PY4 |
DPH |
Alameda Health System |
Q-BH3 |
Q-FUA |
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DPH |
Alameda Health System |
Q-BH3 |
Q-FUA |
30 Days |
Reported |
None |
None |
0.2066 |
None |
63 |
0 |
326 |
0 |
0.1933 |
0 |
N/A |
PY4 |
DPH |
Alameda Health System |
Q-BH3 |
Q-FUA |
7 Days |
Reported |
None |
None |
0.1583 |
None |
49 |
0 |
326 |
0 |
0.1503 |
0 |
N/A |
PY4 |
DPH |
Alameda Health System |
Q-CAC2 |
Q-QPP118 |
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVSD < 40%) |
Reported |
None |
None |
0.9144 |
None |
371 |
0 |
406 |
0 |
0.9138 |
0 |
N/A |
PY4 |
DPH |
Alameda Health System |
Q-CAC3 |
Q-QPP6 |
Coronary Artery Disease (CAD): Antiplatelet Therapy |
Reported |
None |
None |
0.9199 |
None |
911 |
0 |
975 |
0 |
0.9344 |
0 |
N/A |
PY4 |
DPH |
Alameda Health System |
Q-CAC4 |
Q-CMS135 |
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
Reported |
None |
None |
0.8775 |
None |
622 |
0 |
637 |
0 |
0.9765 |
0 |
N/A |
PY4 |
DPH |
Alameda Health System |
Q-CAC5 |
Q-CMS347 |
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease |
Reported |
None |
None |
0.7761 |
None |
3662 |
0 |
4761 |
0 |
0.7692 |
0 |
N/A |
PY4 |
DPH |
Alameda Health System |
Q-CAD3 |
Q-KED |
Kidney Health Evaluation for Patients with Diabetes |
Reported |
None |
None |
0.4676 |
None |
1952 |
0 |
3244 |
0 |
0.6017 |
0 |
N/A |
PY4 |
DPH |
Alameda Health System |
Q-IHE1 |
Q-IHE1 |
Improving Health Equity 1Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
Alameda Health System |
Q-IHE1 |
Q-IHE1 |
Childhood Immunization Status (CIS 10) - -Black/African American |
Reported |
None |
None |
0.3207 |
None |
27 |
0 |
91 |
0 |
0.2967 |
0 |
N/A |
PY4 |
DPH |
Alameda Health System |
Q-IHE2 |
Q-IHE2 |
Improving Health Equity 2Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
Alameda Health System |
Q-IHE2 |
Q-IHE2 |
Exclusive Breast Milk Feeding (PC-05) - -Asian |
Reported |
None |
None |
0.6436 |
None |
29 |
0 |
46 |
0 |
0.6304 |
0 |
N/A |
PY4 |
DPH |
Alameda Health System |
Q-MPH6 |
Q-PRS-E |
Prenatal Immunization Status |
Reported |
None |
None |
0.4544 |
None |
281 |
0 |
619 |
0 |
0.454 |
0 |
N/A |
PY4 |
DPH |
Alameda Health System |
Q-PC12 |
Q-CMS147 |
Preventive Care and Screening: Influenza Immunization |
Reported |
None |
None |
0.6834 |
None |
16683 |
0 |
24553 |
0 |
0.6795 |
0 |
N/A |
PY4 |
DPH |
Alameda Health System |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.7214 |
None |
14394 |
0 |
20513 |
0 |
0.7017 |
0 |
N/A |
PY4 |
DPH |
Alameda Health System |
Q-PS5 |
Q-SSI |
Surgical Site Infection (SSI) |
Reported |
None |
None |
0 |
None |
28 |
0 |
None |
4 |
None |
4 |
N/A |
PY4 |
DMPH |
Antelope Valley Hospital |
Q-CAC4 |
Q-CMS135 |
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
Reported |
None |
None |
0.8775 |
None |
273 |
0 |
306 |
0 |
0.8922 |
0 |
N/A |
PY4 |
DMPH |
Antelope Valley Hospital |
Q-IHE1 |
Q-IHE1 |
Improving Health Equity 1Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DMPH |
Antelope Valley Hospital |
Q-IHE1 |
Q-IHE1 |
Exclusive Breast Milk Feeding (PC-05) - -Black/African American |
Reported |
None |
None |
0.5331 |
None |
33 |
0 |
65 |
0 |
0.5077 |
0 |
N/A |
PY4 |
DMPH |
Antelope Valley Hospital |
Q-IHE2 |
Q-IHE2 |
Improving Health Equity 2Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DMPH |
Antelope Valley Hospital |
Q-IHE2 |
Q-IHE2 |
Cesarean Birth (PC02-CH) - -Black/African American |
Reported |
None |
None |
0.2481 |
None |
36 |
0 |
140 |
0 |
0.2571 |
0 |
N/A |
PY4 |
DMPH |
Antelope Valley Hospital |
Q-OA4 |
Q-LBP |
Use of Imaging Studies for Low Back Pain (LBP) |
Reported |
None |
None |
0.7133 |
None |
390 |
0 |
1207 |
0 |
0.3231 |
0 |
N/A |
PY4 |
DMPH |
Antelope Valley Hospital |
Q-PS1 |
Q-STK-2 |
Discharged on Antithrombotic Therapy |
Reported |
None |
None |
0.9959 |
None |
215 |
0 |
216 |
0 |
0.9954 |
0 |
N/A |
PY4 |
DPH |
Arrowhead Regional Medical Center |
Q-CAC2 |
Q-QPP118 |
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVSD < 40%) |
Reported |
None |
None |
0.6978 |
None |
51 |
0 |
235 |
0 |
0.217 |
0 |
N/A |
PY4 |
DPH |
Arrowhead Regional Medical Center |
Q-CAC3 |
Q-QPP6 |
Coronary Artery Disease (CAD): Antiplatelet Therapy |
Reported |
None |
None |
0.7637 |
None |
85 |
0 |
235 |
0 |
0.3617 |
0 |
N/A |
PY4 |
DPH |
Arrowhead Regional Medical Center |
Q-CAC4 |
Q-CMS135 |
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
Reported |
None |
None |
0.7587 |
None |
738 |
0 |
990 |
0 |
0.7455 |
0 |
N/A |
PY4 |
DPH |
Arrowhead Regional Medical Center |
Q-CAD3 |
Q-KED |
Kidney Health Evaluation for Patients with Diabetes |
Reported |
None |
None |
0.4676 |
None |
1262 |
0 |
2374 |
0 |
0.5316 |
0 |
N/A |
PY4 |
DPH |
Arrowhead Regional Medical Center |
Q-CC1 |
Q-TRC |
Transitions of Care (TRC) |
Reported |
None |
None |
0.78 |
None |
716 |
0 |
720 |
0 |
0.9944 |
0 |
N/A |
PY4 |
DPH |
Arrowhead Regional Medical Center |
Q-IHE1 |
Q-IHE1 |
Improving Health Equity 1Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
Arrowhead Regional Medical Center |
Q-IHE1 |
Q-IHE1 |
Immunizations for Adolescents - -Black/African American |
Reported |
None |
None |
0.309 |
None |
None |
1 |
33 |
0 |
None |
1 |
N/A |
PY4 |
DPH |
Arrowhead Regional Medical Center |
Q-IHE2 |
Q-IHE2 |
Improving Health Equity 2Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
Arrowhead Regional Medical Center |
Q-IHE2 |
Q-IHE2 |
Child and Adolescent Well Care Visits - -Black/African American |
Reported |
None |
None |
0.4915 |
None |
316 |
0 |
662 |
0 |
0.4773 |
0 |
N/A |
PY4 |
DPH |
Arrowhead Regional Medical Center |
Q-PC12 |
Q-CMS147 |
Preventive Care and Screening: Influenza Immunization |
Reported |
None |
None |
0.2933 |
None |
3752 |
0 |
15246 |
0 |
0.2461 |
0 |
N/A |
PY4 |
DPH |
Arrowhead Regional Medical Center |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.8826 |
None |
13075 |
0 |
14844 |
0 |
0.8808 |
0 |
N/A |
PY4 |
DPH |
Arrowhead Regional Medical Center |
Q-PC15 |
Q-WCC |
Weight Assessment & Counseling for Nutrition and Physical Activity for Children & Adolescents |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DPH |
Arrowhead Regional Medical Center |
Q-PC15 |
Q-WCC |
BMI |
Reported |
None |
None |
0.7587 |
None |
3479 |
0 |
4663 |
0 |
0.7461 |
0 |
N/A |
PY4 |
DPH |
Arrowhead Regional Medical Center |
Q-PC15 |
Q-WCC |
Counseling for Nutrition |
Reported |
None |
None |
0.6651 |
None |
3019 |
0 |
4663 |
0 |
0.6474 |
0 |
N/A |
PY4 |
DPH |
Arrowhead Regional Medical Center |
Q-PC15 |
Q-WCC |
Counseling for Physical Activity |
Reported |
None |
None |
0.6466 |
None |
2939 |
0 |
4663 |
0 |
0.6303 |
0 |
N/A |
PY4 |
DMPH |
Bear Valley Community Hospital |
Q-OA3 |
Q-QPP415 |
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older |
Reported |
None |
None |
0.86 |
None |
64 |
0 |
75 |
0 |
0.8533 |
0 |
N/A |
PY4 |
DMPH |
Bear Valley Community Hospital |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.5938 |
None |
940 |
0 |
1679 |
0 |
0.5599 |
0 |
N/A |
PY4 |
DMPH |
Bear Valley Community Hospital |
Q-PC16 |
Q-W30 |
15 Months-30 Months |
Reported |
None |
None |
0.6643 |
None |
18 |
0 |
52 |
0 |
0.3462 |
0 |
N/A |
PY4 |
DMPH |
Bear Valley Community Hospital |
Q-PC16 |
Q-W30 |
Well-Child Visits in the First 30 Months of Life (W30) |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DMPH |
Bear Valley Community Hospital |
Q-PC16 |
Q-W30 |
First 15 Months |
Reported |
None |
None |
0.4499 |
None |
None |
1 |
67 |
0 |
None |
1 |
N/A |
PY4 |
DPH |
Contra Costa Regional Medical Center |
Q-CAC2 |
Q-QPP118 |
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVSD < 40%) |
Reported |
None |
None |
0.8621 |
None |
1038 |
0 |
1213 |
0 |
0.8557 |
0 |
N/A |
PY4 |
DPH |
Contra Costa Regional Medical Center |
Q-CAC3 |
Q-QPP6 |
Coronary Artery Disease (CAD): Antiplatelet Therapy |
Reported |
None |
None |
0.8925 |
None |
2428 |
0 |
2730 |
0 |
0.8894 |
0 |
N/A |
PY4 |
DPH |
Contra Costa Regional Medical Center |
Q-CAC4 |
Q-CMS135 |
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
Reported |
None |
None |
0.8775 |
None |
654 |
0 |
736 |
0 |
0.8886 |
0 |
N/A |
PY4 |
DPH |
Contra Costa Regional Medical Center |
Q-CAD3 |
Q-KED |
Kidney Health Evaluation for Patients with Diabetes |
Reported |
None |
None |
0.4676 |
None |
3762 |
0 |
6319 |
0 |
0.5953 |
0 |
N/A |
PY4 |
DPH |
Contra Costa Regional Medical Center |
Q-MPH6 |
Q-PRS-E |
Prenatal Immunization Status |
Reported |
None |
None |
0.4576 |
None |
468 |
0 |
870 |
0 |
0.5379 |
0 |
N/A |
PY4 |
DPH |
Contra Costa Regional Medical Center |
Q-OA4 |
Q-LBP |
Use of Imaging Studies for Low Back Pain (LBP) |
Reported |
None |
None |
0.8282 |
None |
1143 |
0 |
1379 |
0 |
0.8289 |
0 |
N/A |
PY4 |
DPH |
Contra Costa Regional Medical Center |
Q-PC10 |
Q-LSC |
Lead Screening in Children |
Reported |
None |
None |
0.6131 |
None |
827 |
0 |
1454 |
0 |
0.5688 |
0 |
N/A |
PY4 |
DPH |
Contra Costa Regional Medical Center |
Q-PC11 |
Q-CMS69 |
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan |
Reported |
None |
None |
0.5638 |
None |
22784 |
0 |
43547 |
0 |
0.5232 |
0 |
N/A |
PY4 |
DPH |
Contra Costa Regional Medical Center |
Q-PC12 |
Q-CMS147 |
Preventive Care and Screening: Influenza Immunization |
Reported |
None |
None |
0.7182 |
None |
27113 |
0 |
31525 |
0 |
0.86 |
0 |
N/A |
PY4 |
DPH |
Contra Costa Regional Medical Center |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.8988 |
None |
27559 |
0 |
28288 |
0 |
0.9742 |
0 |
N/A |
PY4 |
DMPH |
Eastern Plumas Health Care |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.5004 |
None |
132 |
0 |
484 |
0 |
0.2727 |
0 |
N/A |
PY4 |
DMPH |
Eastern Plumas Health Care |
Q-PC14 |
Q-CMS138 |
Preventative Care and Screening: Tobacco Use - Screening and Cessation Intervention |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DMPH |
Eastern Plumas Health Care |
Q-PC14 |
Q-CMS138 |
Rate 1 (informational only) |
Reported |
None |
None |
0 |
None |
506 |
0 |
536 |
0 |
0.944 |
0 |
N/A |
PY4 |
DMPH |
Eastern Plumas Health Care |
Q-PC14 |
Q-CMS138 |
Rate 2 |
Reported |
None |
None |
0.7848 |
None |
107 |
0 |
139 |
0 |
0.7698 |
0 |
N/A |
PY4 |
DMPH |
Eastern Plumas Health Care |
Q-PC14 |
Q-CMS138 |
Rate 3 |
Reported |
None |
None |
0.8911 |
None |
474 |
0 |
536 |
0 |
0.8843 |
0 |
N/A |
PY4 |
DMPH |
El Camino Hospital |
Q-IHE2 |
Q-IHE2 |
Improving Health Equity 2Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DMPH |
El Camino Hospital |
Q-IHE2 |
Q-IHE2 |
Exclusive Breast Milk Feeding (PC-05) - -Asian |
Reported |
None |
None |
0.4776 |
None |
None |
1 |
32 |
0 |
None |
1 |
N/A |
PY4 |
DMPH |
El Camino Hospital |
Q-MPH6 |
Q-PRS-E |
Prenatal Immunization Status |
Reported |
None |
None |
0.2258 |
None |
None |
1 |
45 |
0 |
None |
1 |
N/A |
PY4 |
DMPH |
El Centro Regional Medical Center |
Q-CAC3 |
Q-QPP6 |
Coronary Artery Disease (CAD): Antiplatelet Therapy |
Reported |
None |
None |
0.7637 |
None |
40 |
0 |
95 |
0 |
0.4211 |
0 |
N/A |
PY4 |
DMPH |
El Centro Regional Medical Center |
Q-PC11 |
Q-CMS69 |
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan |
Reported |
None |
None |
0.7155 |
None |
2018 |
0 |
2917 |
0 |
0.6918 |
0 |
N/A |
PY4 |
DMPH |
El Centro Regional Medical Center |
Q-PC12 |
Q-CMS147 |
Preventive Care and Screening: Influenza Immunization |
Reported |
None |
None |
0.3176 |
None |
1034 |
0 |
3786 |
0 |
0.2731 |
0 |
N/A |
PY4 |
DMPH |
El Centro Regional Medical Center |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.8624 |
None |
3829 |
0 |
4461 |
0 |
0.8583 |
0 |
N/A |
PY4 |
DMPH |
El Centro Regional Medical Center |
Q-PC3 |
Q-WCV |
Child and Adolescent Well Care Visits |
Reported |
None |
None |
0.5384 |
None |
1009 |
0 |
1906 |
0 |
0.5294 |
0 |
N/A |
PY4 |
DMPH |
Hazel Hawkins Memorial Hospital |
Q-MPH5 |
Q-PPC-PRE |
Prenatal and Postpartum Care: Timeliness of Prenatal Care (PPC-PRE) |
Reported |
None |
None |
0.8864 |
None |
45 |
0 |
51 |
0 |
0.8824 |
0 |
N/A |
PY4 |
DMPH |
Hazel Hawkins Memorial Hospital |
Q-PC9 |
Q-IMA |
Immunizations for Adolescents |
Reported |
None |
None |
0.309 |
None |
16 |
0 |
58 |
0 |
0.2759 |
0 |
N/A |
PY4 |
DMPH |
Hazel Hawkins Memorial Hospital |
Q-PS4 |
Q-CDI |
Reduction in Hospital Acquired Clostridium Difficile Infections |
Reported |
None |
None |
0 |
None |
None |
1 |
None |
1 |
None |
1 |
N/A |
PY4 |
DMPH |
Hazel Hawkins Memorial Hospital |
Q-CAD1 |
Q-HBD |
Comprehensive Diabetes Care: HbA1c Poor Control (>9.0%) (CDC-H9) |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DMPH |
Hazel Hawkins Memorial Hospital |
Q-CAD1 |
Q-HBD |
Black/African-American |
Reported |
None |
None |
N/A |
3 |
None |
1 |
None |
1 |
None |
1 |
N/A |
PY4 |
DMPH |
Hazel Hawkins Memorial Hospital |
Q-CAD1 |
Q-HBD |
Hispanic/Latino |
Reported |
None |
None |
0.3406 |
None |
49 |
0 |
144 |
0 |
0.3403 |
0 |
N/A |
PY4 |
DMPH |
Hazel Hawkins Memorial Hospital |
Q-CAD1 |
Q-HBD |
Total Population |
Reported |
None |
None |
0.3636 |
None |
68 |
0 |
187 |
0 |
0.3636 |
0 |
N/A |
PY4 |
DMPH |
Jerold Phelps Community Hospital |
Q-PC11 |
Q-CMS69 |
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan |
Reported |
None |
None |
0.4955 |
None |
105 |
0 |
271 |
0 |
0.3875 |
0 |
N/A |
PY4 |
DMPH |
Jerold Phelps Community Hospital |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.5004 |
None |
None |
1 |
236 |
0 |
None |
1 |
N/A |
PY4 |
DMPH |
John C Fremont Healthcare District |
Q-CAC1 |
Q-CBP |
Controlling High Blood Pressure (CBP) |
Reported |
None |
None |
0.5061 |
None |
70 |
0 |
144 |
0 |
0.4861 |
0 |
N/A |
PY4 |
DMPH |
John C Fremont Healthcare District |
Q-PC2 |
Q-CCS |
Cervical Cancer Screening (CCS) |
Reported |
None |
None |
0.518 |
None |
151 |
0 |
585 |
0 |
0.2581 |
0 |
N/A |
PY4 |
DMPH |
Kaweah Delta Health Care District |
Q-BH3 |
Q-FUA |
30 Days |
Reported |
None |
None |
0.1075 |
None |
None |
1 |
47 |
0 |
None |
1 |
N/A |
PY4 |
DMPH |
Kaweah Delta Health Care District |
Q-BH3 |
Q-FUA |
7 Days |
Reported |
None |
None |
0.157 |
None |
None |
1 |
47 |
0 |
None |
1 |
N/A |
PY4 |
DMPH |
Kaweah Delta Health Care District |
Q-BH3 |
Q-FUA |
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DMPH |
Kaweah Delta Health Care District |
Q-CAC5 |
Q-CMS347 |
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease |
Reported |
None |
None |
0.6667 |
None |
708 |
0 |
1100 |
0 |
0.6436 |
0 |
N/A |
PY4 |
DMPH |
Kaweah Delta Health Care District |
Q-CAD3 |
Q-KED |
Kidney Health Evaluation for Patients with Diabetes |
Reported |
None |
None |
0.3096 |
None |
200 |
0 |
685 |
0 |
0.292 |
0 |
N/A |
PY4 |
DMPH |
Kaweah Delta Health Care District |
Q-PC3 |
Q-WCV |
Child and Adolescent Well Care Visits |
Reported |
None |
None |
0.6075 |
None |
3036 |
0 |
5009 |
0 |
0.6061 |
0 |
N/A |
PY4 |
DMPH |
Kaweah Delta Health Care District |
Q-PC9 |
Q-IMA |
Immunizations for Adolescents |
Reported |
None |
None |
0.3816 |
None |
121 |
0 |
329 |
0 |
0.3678 |
0 |
N/A |
PY4 |
DPH |
Kern Medical Center |
Q-BH2 |
Q-DRR-E |
Depression Remission or Response for Adolescents and Adults (DRR-E) |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DPH |
Kern Medical Center |
Q-BH2 |
Q-DRR-E |
Depression Remission (Adolescents) - informational only |
Reported |
None |
None |
N/A |
3 |
None |
1 |
None |
4 |
None |
1 |
N/A |
PY4 |
DPH |
Kern Medical Center |
Q-BH2 |
Q-DRR-E |
Depression Response (Adolescents) - informational only |
Reported |
None |
None |
N/A |
3 |
None |
1 |
None |
4 |
None |
1 |
N/A |
PY4 |
DPH |
Kern Medical Center |
Q-BH2 |
Q-DRR-E |
Follow-Up PHQ-9 (Adolescents) - informational only |
Reported |
None |
None |
N/A |
3 |
11 |
0 |
None |
4 |
None |
4 |
N/A |
PY4 |
DPH |
Kern Medical Center |
Q-BH2 |
Q-DRR-E |
Depression Remission (Adults) |
Reported |
None |
None |
0.0984 |
None |
29 |
0 |
314 |
0 |
0.0924 |
0 |
N/A |
PY4 |
DPH |
Kern Medical Center |
Q-BH2 |
Q-DRR-E |
Depression Response (Adults) |
Reported |
None |
None |
0.1465 |
None |
42 |
0 |
314 |
0 |
0.1338 |
0 |
N/A |
PY4 |
DPH |
Kern Medical Center |
Q-BH2 |
Q-DRR-E |
Follow-Up PHQ-9 (Adults) |
Reported |
None |
None |
0.3851 |
None |
111 |
0 |
314 |
0 |
0.3535 |
0 |
N/A |
PY4 |
DPH |
Kern Medical Center |
Q-CAC2 |
Q-QPP118 |
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVSD < 40%) |
Reported |
None |
None |
0.8855 |
None |
164 |
0 |
186 |
0 |
0.8817 |
0 |
N/A |
PY4 |
DPH |
Kern Medical Center |
Q-CAC3 |
Q-QPP6 |
Coronary Artery Disease (CAD): Antiplatelet Therapy |
Reported |
None |
None |
0.8937 |
None |
310 |
0 |
348 |
0 |
0.8908 |
0 |
N/A |
PY4 |
DPH |
Kern Medical Center |
Q-CAC4 |
Q-CMS135 |
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
Reported |
None |
None |
0.8775 |
None |
68 |
0 |
69 |
0 |
0.9855 |
0 |
N/A |
PY4 |
DPH |
Kern Medical Center |
Q-CAD3 |
Q-KED |
Kidney Health Evaluation for Patients with Diabetes |
Reported |
None |
None |
0.4676 |
None |
1225 |
0 |
2315 |
0 |
0.5292 |
0 |
N/A |
PY4 |
DPH |
Kern Medical Center |
Q-CC2 |
Q-PCR |
Plan All-Cause Readmissions (PCR) |
Reported |
None |
None |
0 |
None |
61 |
0 |
60.12 |
0 |
1.0146 |
0 |
N/A |
PY4 |
DPH |
Kern Medical Center |
Q-IHE1 |
Q-IHE1 |
Improving Health Equity 1Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
Kern Medical Center |
Q-IHE1 |
Q-IHE1 |
Controlling High Blood Pressure (CBP) - -Black/African American |
Reported |
None |
None |
0.5292 |
None |
149 |
0 |
290 |
0 |
0.5138 |
0 |
N/A |
PY4 |
DPH |
Kern Medical Center |
Q-IHE2 |
Q-IHE2 |
Improving Health Equity 2Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
Kern Medical Center |
Q-IHE2 |
Q-IHE2 |
Exclusive Breast Milk Feeding (PC-05) - -Black/African American |
Reported |
None |
None |
0.5152 |
None |
40 |
0 |
82 |
0 |
0.4878 |
0 |
N/A |
PY4 |
DPH |
Kern Medical Center |
Q-OA1 |
Q-URI |
Appropriate Treatment for Upper Respiratory Infection (URI) |
Reported |
None |
None |
0.9434 |
None |
265 |
0 |
267 |
0 |
0.9925 |
0 |
N/A |
PY4 |
DPH |
Kern Medical Center |
Q-OA4 |
Q-LBP |
Use of Imaging Studies for Low Back Pain (LBP) |
Reported |
None |
None |
0.7133 |
None |
137 |
0 |
198 |
0 |
0.6919 |
0 |
N/A |
PY4 |
DPH |
Kern Medical Center |
Q-PC11 |
Q-CMS69 |
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan |
Reported |
None |
None |
0.5256 |
None |
7457 |
0 |
15510 |
0 |
0.4808 |
0 |
N/A |
PY4 |
DPH |
Kern Medical Center |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.6565 |
None |
5493 |
0 |
8725 |
0 |
0.6296 |
0 |
N/A |
PY4 |
DPH |
Kern Medical Center |
Q-PS5 |
Q-SSI |
Surgical Site Infection (SSI) |
Reported |
None |
None |
0 |
None |
None |
1 |
None |
1 |
None |
1 |
N/A |
PY4 |
DMPH |
Kern Valley Healthcare District |
Q-PC11 |
Q-CMS69 |
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan |
Reported |
None |
None |
0.4955 |
None |
237 |
0 |
960 |
0 |
0.2469 |
0 |
N/A |
PY4 |
DMPH |
Kern Valley Healthcare District |
Q-CAD1 |
Q-HBD |
Comprehensive Diabetes Care: HbA1c Poor Control (>9.0%) (CDC-H9)* |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DMPH |
Kern Valley Healthcare District |
Q-CAD1 |
Q-HBD |
Black/African-American |
Reported |
None |
None |
0.3406 |
None |
None |
1 |
72 |
0 |
None |
1 |
N/A |
PY4 |
DMPH |
Kern Valley Healthcare District |
Q-CAD1 |
Q-HBD |
Hispanic/Latino |
Reported |
None |
None |
0.3406 |
None |
21 |
0 |
72 |
0 |
0.2917 |
0 |
N/A |
PY4 |
DMPH |
Kern Valley Healthcare District |
Q-CAD1 |
Q-HBD |
Total Population |
Reported |
None |
None |
0.3406 |
None |
22 |
0 |
72 |
0 |
0.3056 |
0 |
N/A |
PY4 |
DMPH |
Lompoc Valley Medical Center |
Q-CAD3 |
Q-KED |
Kidney Health Evaluation for Patients with Diabetes |
Reported |
None |
None |
0.2687 |
None |
39 |
0 |
179 |
0 |
0.2179 |
0 |
N/A |
PY4 |
DMPH |
Lompoc Valley Medical Center |
Q-MPH1 |
Q-PC02 |
Cesarean Birth (PC02-CH) |
Reported |
None |
None |
0.2481 |
None |
16 |
0 |
47 |
0 |
0.3404 |
0 |
N/A |
PY4 |
DMPH |
Lompoc Valley Medical Center |
Q-MPH4 |
Q-PPC-PST |
Prenatal and Postpartum Care: Postpartum Care (PPC-PST) |
Reported |
None |
None |
0.7111 |
None |
19 |
0 |
32 |
0 |
0.5938 |
0 |
N/A |
PY4 |
DMPH |
Lompoc Valley Medical Center |
Q-MPH5 |
Q-PPC-PRE |
Prenatal and Postpartum Care: Timeliness of Prenatal Care (PPC-PRE) |
Reported |
None |
None |
0.7932 |
None |
None |
1 |
32 |
0 |
None |
1 |
N/A |
PY4 |
DMPH |
Lompoc Valley Medical Center |
Q-PC11 |
Q-CMS69 |
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan |
Reported |
None |
None |
0.4955 |
None |
896 |
0 |
3547 |
0 |
0.2526 |
0 |
N/A |
PY4 |
DMPH |
Lompoc Valley Medical Center |
Q-PC12 |
Q-CMS147 |
Preventive Care and Screening: Influenza Immunization |
Reported |
None |
None |
0.2671 |
None |
671 |
0 |
3412 |
0 |
0.1967 |
0 |
N/A |
PY4 |
DMPH |
Lompoc Valley Medical Center |
Q-PC4 |
Q-CIS |
Childhood Immunization Status (CIS 10) |
Reported |
None |
None |
0.3187 |
None |
47 |
0 |
162 |
0 |
0.2901 |
0 |
N/A |
PY4 |
DMPH |
Lompoc Valley Medical Center |
Q-PC7 |
Q-DEV |
Developmental Screening in the First Three Years of Life |
Reported |
None |
None |
0.3665 |
None |
225 |
0 |
394 |
0 |
0.5711 |
0 |
N/A |
PY4 |
DMPH |
Lompoc Valley Medical Center |
Q-PC8 |
Q-CMS349 |
HIV Screening Measure |
Reported |
None |
None |
0.2809 |
None |
338 |
0 |
1394 |
0 |
0.2425 |
0 |
N/A |
PY4 |
DMPH |
Lompoc Valley Medical Center |
Q-CAD1 |
Q-HBD |
Comprehensive Diabetes Care: HbA1c Poor Control (>9.0%) (CDC-H9)* |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DMPH |
Lompoc Valley Medical Center |
Q-CAD1 |
Q-HBD |
Black/African-American |
Reported |
None |
None |
N/A |
3 |
None |
1 |
None |
1 |
None |
1 |
N/A |
PY4 |
DMPH |
Lompoc Valley Medical Center |
Q-CAD1 |
Q-HBD |
Hispanic/Latino |
Reported |
None |
None |
0.3406 |
None |
28 |
0 |
87 |
0 |
0.3218 |
0 |
N/A |
PY4 |
DMPH |
Lompoc Valley Medical Center |
Q-CAD1 |
Q-HBD |
Total Population |
Reported |
None |
None |
0.3427 |
None |
60 |
0 |
175 |
0 |
0.3429 |
0 |
N/A |
PY4 |
DPH |
Los Angeles County Health System |
Q-BH3 |
Q-FUA |
30 Days |
Reported |
None |
None |
0.2489 |
None |
105 |
0 |
437 |
0 |
0.2403 |
0 |
N/A |
PY4 |
DPH |
Los Angeles County Health System |
Q-BH3 |
Q-FUA |
7 Days |
Reported |
None |
None |
0.161 |
None |
67 |
0 |
437 |
0 |
0.1533 |
0 |
N/A |
PY4 |
DPH |
Los Angeles County Health System |
Q-BH3 |
Q-FUA |
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DPH |
Los Angeles County Health System |
Q-BH5 |
Q-FUI |
30 Days |
Reported |
None |
None |
0.3894 |
None |
56 |
0 |
159 |
0 |
0.3522 |
0 |
N/A |
PY4 |
DPH |
Los Angeles County Health System |
Q-BH5 |
Q-FUI |
7 Days |
Reported |
None |
None |
0.2529 |
None |
36 |
0 |
159 |
0 |
0.2264 |
0 |
N/A |
PY4 |
DPH |
Los Angeles County Health System |
Q-BH5 |
Q-FUI |
Follow-Up After High-Intensity Care for Substance Use Disorder (FUI)* |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DPH |
Los Angeles County Health System |
Q-CAC2 |
Q-QPP118 |
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVSD < 40%) |
Reported |
None |
None |
0.9199 |
None |
3826 |
0 |
4137 |
0 |
0.9248 |
0 |
N/A |
PY4 |
DPH |
Los Angeles County Health System |
Q-CAC3 |
Q-QPP6 |
Coronary Artery Disease (CAD): Antiplatelet Therapy |
Reported |
None |
None |
0.8971 |
None |
6649 |
0 |
7432 |
0 |
0.8946 |
0 |
N/A |
PY4 |
DPH |
Los Angeles County Health System |
Q-CAC4 |
Q-CMS135 |
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
Reported |
None |
None |
0.8775 |
None |
3398 |
0 |
3564 |
0 |
0.9534 |
0 |
N/A |
PY4 |
DPH |
Los Angeles County Health System |
Q-CAD3 |
Q-KED |
Kidney Health Evaluation for Patients with Diabetes |
Reported |
None |
None |
0.4676 |
None |
10248 |
0 |
17010 |
0 |
0.6025 |
0 |
N/A |
PY4 |
DPH |
Los Angeles County Health System |
Q-CAR2 |
Q-PCE |
Bronchodilator |
Reported |
None |
None |
0.7872 |
None |
68 |
0 |
91 |
0 |
0.7473 |
0 |
N/A |
PY4 |
DPH |
Los Angeles County Health System |
Q-CAR2 |
Q-PCE |
Pharmacotherapy Management of COPD Exacerbation (PCE) |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DPH |
Los Angeles County Health System |
Q-CAR2 |
Q-PCE |
Systemic Corticosteroid |
Reported |
None |
None |
0.636 |
None |
51 |
0 |
91 |
0 |
0.5604 |
0 |
N/A |
PY4 |
DPH |
Los Angeles County Health System |
Q-IHE1 |
Q-IHE1 |
Developmental Screening in the First Three Years of Life - -Black/African American |
Reported |
None |
None |
0.3112 |
None |
197 |
0 |
646 |
0 |
0.305 |
0 |
N/A |
PY4 |
DPH |
Los Angeles County Health System |
Q-IHE1 |
Q-IHE1 |
Improving Health Equity 1Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
Los Angeles County Health System |
Q-IHE2 |
Q-IHE2 |
Chlamydia Screening in Women (CHL) - -Asian |
Reported |
None |
None |
0.5599 |
None |
96 |
0 |
175 |
0 |
0.5486 |
0 |
N/A |
PY4 |
DPH |
Los Angeles County Health System |
Q-IHE2 |
Q-IHE2 |
Improving Health Equity 2Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
Los Angeles County Health System |
Q-MPH1 |
Q-PC02 |
Cesarean Birth (PC02-CH) |
Reported |
None |
None |
0.2481 |
None |
206 |
0 |
792 |
0 |
0.2601 |
0 |
N/A |
PY4 |
DPH |
Los Angeles County Health System |
Q-OA4 |
Q-LBP |
Use of Imaging Studies for Low Back Pain (LBP) |
Reported |
None |
None |
0.8282 |
None |
1854 |
0 |
2199 |
0 |
0.8431 |
0 |
N/A |
PY4 |
DPH |
Los Angeles County Health System |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.8988 |
None |
74182 |
0 |
80242 |
0 |
0.9245 |
0 |
N/A |
PY4 |
DMPH |
Mammoth Hospital |
Q-PC11 |
Q-CMS69 |
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan |
Reported |
None |
None |
0.5646 |
None |
337 |
0 |
643 |
0 |
0.5241 |
0 |
N/A |
PY4 |
DMPH |
Mammoth Hospital |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.6928 |
None |
617 |
0 |
921 |
0 |
0.6699 |
0 |
N/A |
PY4 |
DMPH |
Mammoth Hospital |
Q-CAD1 |
Q-HBD |
Comprehensive Diabetes Care: HbA1c Poor Control (>9.0%) (CDC-H9)* |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DMPH |
Mammoth Hospital |
Q-CAD1 |
Q-HBD |
Black/African-American |
Reported |
None |
None |
N/A |
3 |
0 |
0 |
0 |
0 |
0 |
0 |
N/A |
PY4 |
DMPH |
Mammoth Hospital |
Q-CAD1 |
Q-HBD |
Hispanic/Latino |
Reported |
None |
None |
0.3406 |
None |
None |
1 |
45 |
0 |
None |
1 |
N/A |
PY4 |
DMPH |
Mammoth Hospital |
Q-CAD1 |
Q-HBD |
Total Population |
Reported |
None |
None |
0.3406 |
None |
15 |
0 |
61 |
0 |
0.2459 |
0 |
N/A |
PY4 |
DMPH |
Marin General Hospital |
Q-MPH4 |
Q-PPC-PST |
Prenatal and Postpartum Care: Postpartum Care (PPC-PST) |
Reported |
None |
None |
0.837 |
None |
201 |
0 |
224 |
0 |
0.8973 |
0 |
N/A |
PY4 |
DMPH |
Mayers Memorial Hospital District |
Q-PC12 |
Q-CMS147 |
Preventive Care and Screening: Influenza Immunization |
Reported |
None |
None |
0.7182 |
None |
73 |
0 |
90 |
0 |
0.8111 |
0 |
N/A |
PY4 |
DMPH |
Modoc Medical Center |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.614 |
None |
538 |
0 |
924 |
0 |
0.5823 |
0 |
N/A |
PY4 |
DPH |
Natividad Medical Center |
Q-BH3 |
Q-FUA |
30 Days |
Reported |
None |
None |
0.1075 |
None |
None |
1 |
111 |
0 |
None |
1 |
N/A |
PY4 |
DPH |
Natividad Medical Center |
Q-BH3 |
Q-FUA |
7 Days |
Reported |
None |
None |
0.071 |
None |
None |
1 |
111 |
0 |
None |
1 |
N/A |
PY4 |
DPH |
Natividad Medical Center |
Q-BH3 |
Q-FUA |
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DPH |
Natividad Medical Center |
Q-CAC2 |
Q-QPP118 |
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVSD < 40%) |
Reported |
None |
None |
0.7968 |
None |
130 |
0 |
166 |
0 |
0.7831 |
0 |
N/A |
PY4 |
DPH |
Natividad Medical Center |
Q-CAC3 |
Q-QPP6 |
Coronary Artery Disease (CAD): Antiplatelet Therapy |
Reported |
None |
None |
0.7944 |
None |
224 |
0 |
287 |
0 |
0.7805 |
0 |
N/A |
PY4 |
DPH |
Natividad Medical Center |
Q-CAC4 |
Q-CMS135 |
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
Reported |
None |
None |
0.8537 |
None |
40 |
0 |
47 |
0 |
0.8511 |
0 |
N/A |
PY4 |
DPH |
Natividad Medical Center |
Q-CAD3 |
Q-KED |
Kidney Health Evaluation for Patients with Diabetes |
Reported |
None |
None |
0.3971 |
None |
619 |
0 |
1590 |
0 |
0.3893 |
0 |
N/A |
PY4 |
DPH |
Natividad Medical Center |
Q-MPH6 |
Q-PRS-E |
Prenatal Immunization Status |
Reported |
None |
None |
0.4576 |
None |
160 |
0 |
277 |
0 |
0.5776 |
0 |
N/A |
PY4 |
DPH |
Natividad Medical Center |
Q-OA4 |
Q-LBP |
Use of Imaging Studies for Low Back Pain (LBP) |
Reported |
None |
None |
0.8282 |
None |
243 |
0 |
263 |
0 |
0.924 |
0 |
N/A |
PY4 |
DPH |
Natividad Medical Center |
Q-PC11 |
Q-CMS69 |
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan |
Reported |
None |
None |
0.5394 |
None |
8898 |
0 |
17937 |
0 |
0.4961 |
0 |
N/A |
PY4 |
DPH |
Natividad Medical Center |
Q-PC12 |
Q-CMS147 |
Preventive Care and Screening: Influenza Immunization |
Reported |
None |
None |
0.5975 |
None |
15010 |
0 |
25697 |
0 |
0.5841 |
0 |
N/A |
PY4 |
DPH |
Natividad Medical Center |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.6745 |
None |
14356 |
0 |
22100 |
0 |
0.6496 |
0 |
N/A |
PY4 |
DPH |
Natividad Medical Center |
Q-PC15 |
Q-WCC |
BMI |
Reported |
None |
None |
0.8486 |
None |
9809 |
0 |
11594 |
0 |
0.846 |
0 |
N/A |
PY4 |
DPH |
Natividad Medical Center |
Q-PC15 |
Q-WCC |
Counseling for Nutrition |
Reported |
None |
None |
0.7832 |
None |
9027 |
0 |
11594 |
0 |
0.7786 |
0 |
N/A |
PY4 |
DPH |
Natividad Medical Center |
Q-PC15 |
Q-WCC |
Counseling for Physical Activity |
Reported |
None |
None |
0.7801 |
None |
9027 |
0 |
11594 |
0 |
0.7786 |
0 |
N/A |
PY4 |
DPH |
Natividad Medical Center |
Q-PC15 |
Q-WCC |
Weight Assessment & Counseling for Nutrition and Physical Activity for Children & Adolescents |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DPH |
Natividad Medical Center |
Q-CAD1 |
Q-HBD |
Comprehensive Diabetes Care: HbA1c Poor Control (>9.0%) (CDC-H9)* |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
Natividad Medical Center |
Q-CAD1 |
Q-HBD |
Black/African-American |
Reported |
None |
None |
0.3555 |
None |
15 |
0 |
42 |
0 |
0.3571 |
0 |
N/A |
PY4 |
DPH |
Natividad Medical Center |
Q-CAD1 |
Q-HBD |
Hispanic/Latino |
Reported |
None |
None |
0.369 |
None |
380 |
0 |
1021 |
0 |
0.3722 |
0 |
N/A |
PY4 |
DPH |
Natividad Medical Center |
Q-CAD1 |
Q-HBD |
Total Population |
Reported |
None |
None |
0.3436 |
None |
490 |
0 |
1425 |
0 |
0.3439 |
0 |
N/A |
PY4 |
DMPH |
Northern Inyo Hospital |
Q-MPH4 |
Q-PPC-PST |
Prenatal and Postpartum Care: Postpartum Care (PPC-PST) |
Reported |
None |
None |
0.7111 |
None |
20 |
0 |
34 |
0 |
0.5882 |
0 |
N/A |
PY4 |
DMPH |
Northern Inyo Hospital |
Q-MPH5 |
Q-PPC-PRE |
Prenatal and Postpartum Care: Timeliness of Prenatal Care (PPC-PRE) |
Reported |
None |
None |
0.7932 |
None |
18 |
0 |
35 |
0 |
0.5143 |
0 |
N/A |
PY4 |
DMPH |
Oak Valley Hospital District |
Q-CAC1 |
Q-CBP |
Controlling High Blood Pressure (CBP) |
Reported |
None |
None |
0.5474 |
None |
385 |
0 |
721 |
0 |
0.534 |
0 |
N/A |
PY4 |
DMPH |
Oak Valley Hospital District |
Q-CAC3 |
Q-QPP6 |
Coronary Artery Disease (CAD): Antiplatelet Therapy |
Reported |
None |
None |
0.7637 |
None |
485 |
0 |
661 |
0 |
0.7337 |
0 |
N/A |
PY4 |
DMPH |
Oak Valley Hospital District |
Q-CAD3 |
Q-KED |
Kidney Health Evaluation for Patients with Diabetes |
Reported |
None |
None |
0.4676 |
None |
392 |
0 |
554 |
0 |
0.7076 |
0 |
N/A |
PY4 |
DMPH |
Oak Valley Hospital District |
Q-MPH6 |
Q-PRS-E |
Prenatal Immunization Status |
Reported |
None |
None |
0.4576 |
None |
38 |
0 |
63 |
0 |
0.6032 |
0 |
N/A |
PY4 |
DMPH |
Oak Valley Hospital District |
Q-PC11 |
Q-CMS69 |
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan |
Reported |
None |
None |
0.4955 |
None |
395 |
0 |
2486 |
0 |
0.1589 |
0 |
N/A |
PY4 |
DMPH |
Oak Valley Hospital District |
Q-PC12 |
Q-CMS147 |
Preventive Care and Screening: Influenza Immunization |
Reported |
None |
None |
0.2671 |
None |
834 |
0 |
3961 |
0 |
0.2106 |
0 |
N/A |
PY4 |
DMPH |
Oak Valley Hospital District |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.7799 |
None |
1824 |
0 |
2379 |
0 |
0.7667 |
0 |
N/A |
PY4 |
DMPH |
Oak Valley Hospital District |
Q-PC8 |
Q-CMS349 |
HIV Screening Measure |
Reported |
None |
None |
0.3029 |
None |
436 |
0 |
1633 |
0 |
0.267 |
0 |
N/A |
PY4 |
DMPH |
Palo Verde |
Q-EC1 |
Q-QPP47 |
Advance Care Plan |
Reported |
None |
None |
0.4799 |
None |
0 |
0 |
270 |
0 |
0 |
0 |
N/A |
PY4 |
DMPH |
Palo Verde |
Q-PC11 |
Q-CMS69 |
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan |
Reported |
None |
None |
0.4955 |
None |
None |
1 |
471 |
0 |
None |
1 |
N/A |
PY4 |
DMPH |
Palo Verde |
Q-PC12 |
Q-CMS147 |
Preventive Care and Screening: Influenza Immunization |
Reported |
None |
None |
0.6551 |
None |
186 |
0 |
287 |
0 |
0.6481 |
0 |
N/A |
PY4 |
DMPH |
Palo Verde |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.5004 |
None |
159 |
0 |
585 |
0 |
0.2718 |
0 |
N/A |
PY4 |
DMPH |
Palo Verde |
Q-PC14 |
Q-CMS138 |
Preventative Care and Screening: Tobacco Use - Screening and Cessation Intervention |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DMPH |
Palo Verde |
Q-PC14 |
Q-CMS138 |
Rate 1 (informational only) |
Reported |
None |
None |
0 |
None |
549 |
0 |
555 |
0 |
0.9892 |
0 |
N/A |
PY4 |
DMPH |
Palo Verde |
Q-PC14 |
Q-CMS138 |
Rate 2 |
Reported |
None |
None |
0.812 |
None |
116 |
0 |
145 |
0 |
0.8 |
0 |
N/A |
PY4 |
DMPH |
Palo Verde |
Q-PC14 |
Q-CMS138 |
Rate 3 |
Reported |
None |
None |
0.7542 |
None |
116 |
0 |
555 |
0 |
0.209 |
0 |
N/A |
PY4 |
DMPH |
Palomar Medical Center |
Q-CAC4 |
Q-CMS135 |
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
Reported |
None |
None |
0.7878 |
None |
56 |
0 |
72 |
0 |
0.7778 |
0 |
N/A |
PY4 |
DMPH |
Pioneer Memorial Healthcare District |
Q-CAD1 |
Q-HBD |
Comprehensive Diabetes Care: HbA1c Poor Control (>9.0%) (CDC-H9)* |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DMPH |
Pioneer Memorial Healthcare District |
Q-CAD1 |
Q-HBD |
Black/African-American |
Reported |
None |
None |
N/A |
3 |
0 |
0 |
0 |
0 |
0 |
0 |
N/A |
PY4 |
DMPH |
Pioneer Memorial Healthcare District |
Q-CAD1 |
Q-HBD |
Hispanic/Latino |
Reported |
None |
None |
0.5044 |
None |
220 |
0 |
421 |
0 |
0.5226 |
0 |
N/A |
PY4 |
DMPH |
Pioneer Memorial Healthcare District |
Q-CAD1 |
Q-HBD |
Total Population |
Reported |
None |
None |
0.4943 |
None |
246 |
0 |
481 |
0 |
0.5114 |
0 |
N/A |
PY4 |
DMPH |
Pioneer Memorial Healthcare District |
Q-MPH1 |
Q-PC02 |
Cesarean Birth (PC02-CH)Â |
Reported |
None |
None |
0.2200Â |
None |
69 |
0 |
370 |
0 |
0.1865Â |
0 |
N/A |
PY4 |
DMPH |
Pioneer Memorial Healthcare District |
Q-MPH3 |
Q-PC05 |
Exclusive Breast Milk Feeding (PC-05)Â |
Reported |
None |
None |
0.4776Â |
None |
332 |
0 |
974 |
0 |
0.3409Â |
0 |
N/A |
PY4 |
DMPH |
Pioneer Memorial Healthcare District |
Q-PC1 |
Q-BCS |
Breast Cancer Screening (BCS)Â |
Reported |
None |
None |
0.5543Â |
None |
230 |
0 |
422 |
0 |
0.5450Â |
0 |
N/A |
PY4 |
DMPH |
Pioneer Memorial Healthcare District |
Q-PC10 |
Q-LSC |
Lead Screening in Children |
Reported |
None |
None |
0.6131Â |
None |
22 |
0 |
148 |
0 |
0.1486Â |
0 |
N/A |
PY4 |
DMPH |
Pioneer Memorial Healthcare District |
Q-PC9 |
Q-IMA |
Immunizations for Adolescents |
Reported |
None |
None |
0.3216Â |
None |
28 |
0 |
93 |
0 |
0.3011Â |
0 |
N/A |
PY4 |
DMPH |
Plumas District Hospital |
Q-PC3 |
Q-WCV |
Child and Adolescent Well Care Visits |
Reported |
None |
None |
0.3941Â |
None |
194 |
0 |
699 |
0 |
0.2775Â |
0 |
N/A |
PY4 |
DMPH |
Plumas District Hospital |
Q-PC6 |
Q-CMS130 |
Colorectal Cancer Screening |
Reported |
None |
None |
0.4176Â |
None |
123 |
0 |
310 |
0 |
0.3968Â |
0 |
N/A |
PY4 |
DPH |
Riverside University Health System |
Q-BH3 |
Q-FUA |
30 Days |
Reported |
None |
None |
0.326 |
None |
60 |
0 |
149 |
0 |
0.4027 |
0 |
N/A |
PY4 |
DPH |
Riverside University Health System |
Q-BH3 |
Q-FUA |
7 Days |
Reported |
None |
None |
0.2298 |
None |
46 |
0 |
149 |
0 |
0.3087 |
0 |
N/A |
PY4 |
DPH |
Riverside University Health System |
Q-BH3 |
Q-FUA |
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DPH |
Riverside University Health System |
Q-BH5 |
Q-FUI |
30 Days |
Reported |
None |
None |
0.4975 |
None |
32 |
0 |
67 |
0 |
0.4776 |
0 |
N/A |
PY4 |
DPH |
Riverside University Health System |
Q-BH5 |
Q-FUI |
7 Days |
Reported |
None |
None |
0.2775 |
None |
17 |
0 |
67 |
0 |
0.2537 |
0 |
N/A |
PY4 |
DPH |
Riverside University Health System |
Q-BH5 |
Q-FUI |
Follow-Up After High-Intensity Care for Substance Use Disorder (FUI)* |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DPH |
Riverside University Health System |
Q-CAC2 |
Q-QPP118 |
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVSD < 40%) |
Reported |
None |
None |
0.8142 |
None |
1251 |
0 |
1559 |
0 |
0.8024 |
0 |
N/A |
PY4 |
DPH |
Riverside University Health System |
Q-CAC3 |
Q-QPP6 |
Coronary Artery Disease (CAD): Antiplatelet Therapy |
Reported |
None |
None |
0.8026 |
None |
1501 |
0 |
1901 |
0 |
0.7896 |
0 |
N/A |
PY4 |
DPH |
Riverside University Health System |
Q-CAC4 |
Q-CMS135 |
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
Reported |
None |
None |
0.8775 |
None |
489 |
0 |
544 |
0 |
0.8989 |
0 |
N/A |
PY4 |
DPH |
Riverside University Health System |
Q-CAC5 |
Q-CMS347 |
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease |
Reported |
None |
None |
0.7051 |
None |
4557 |
0 |
6601 |
0 |
0.6903 |
0 |
N/A |
PY4 |
DPH |
Riverside University Health System |
Q-CAD3 |
Q-KED |
Kidney Health Evaluation for Patients with Diabetes |
Reported |
None |
None |
0.4391 |
None |
2412 |
0 |
5533 |
0 |
0.4359 |
0 |
N/A |
PY4 |
DPH |
Riverside University Health System |
Q-EC1 |
Q-QPP47 |
Advance Care Plan |
Reported |
None |
None |
0.6393 |
None |
2674 |
0 |
4397 |
0 |
0.6081 |
0 |
N/A |
PY4 |
DPH |
Riverside University Health System |
Q-IHE1 |
Q-IHE1 |
Preventative Care and Screening: Tobacco Use - Screening and Cessation Intervention - Rate 1 (informational only) -Native Hawaiian/Pacific Islander |
Reported |
None |
None |
0 |
None |
107 |
0 |
122 |
0 |
0.877 |
0 |
N/A |
PY4 |
DPH |
Riverside University Health System |
Q-IHE1 |
Q-IHE1 |
Preventative Care and Screening: Tobacco Use - Screening and Cessation Intervention - Rate 2 -Native Hawaiian/Pacific Islander |
Reported |
None |
None |
0.4738 |
None |
14 |
0 |
33 |
0 |
0.4242 |
0 |
N/A |
PY4 |
DPH |
Riverside University Health System |
Q-IHE1 |
Q-IHE1 |
Preventative Care and Screening: Tobacco Use - Screening and Cessation Intervention - Rate 3 -Native Hawaiian/Pacific Islander |
Reported |
None |
None |
0.7813 |
None |
93 |
0 |
122 |
0 |
0.7623 |
0 |
N/A |
PY4 |
DPH |
Riverside University Health System |
Q-IHE1 |
Q-IHE1 |
Improving Health Equity 1Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
Riverside University Health System |
Q-OA4 |
Q-LBP |
Use of Imaging Studies for Low Back Pain (LBP) |
Reported |
None |
None |
0.8109 |
None |
987 |
0 |
1220 |
0 |
0.809 |
0 |
N/A |
PY4 |
DPH |
Riverside University Health System |
Q-PC12 |
Q-CMS147 |
Preventive Care and Screening: Influenza Immunization |
Reported |
None |
None |
0.5067 |
None |
13418 |
0 |
27769 |
0 |
0.4832 |
0 |
N/A |
PY4 |
DPH |
Riverside University Health System |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.8988 |
None |
33125 |
0 |
34614 |
0 |
0.957 |
0 |
N/A |
PY4 |
DPH |
Riverside University Health System |
Q-PC15 |
Q-WCC |
BMI |
Reported |
None |
None |
0.8681 |
None |
4360 |
0 |
5025 |
0 |
0.8677 |
0 |
N/A |
PY4 |
DPH |
Riverside University Health System |
Q-PC15 |
Q-WCC |
Counseling for Nutrition |
Reported |
None |
None |
0.7801 |
None |
3895 |
0 |
5025 |
0 |
0.7751 |
0 |
N/A |
PY4 |
DPH |
Riverside University Health System |
Q-PC15 |
Q-WCC |
Counseling for Physical Activity |
Reported |
None |
None |
0.7784 |
None |
3903 |
0 |
5025 |
0 |
0.7767 |
0 |
N/A |
PY4 |
DPH |
Riverside University Health System |
Q-PC15 |
Q-WCC |
Weight Assessment & Counseling for Nutrition and Physical Activity for Children & Adolescents |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DMPH |
Salinas Valley Memorial Healthcare System |
Q-CAC2 |
Q-QPP118 |
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVSD < 40%) |
Reported |
None |
None |
0.8965 |
None |
396 |
0 |
443 |
0 |
0.8939 |
0 |
N/A |
PY4 |
DMPH |
Salinas Valley Memorial Healthcare System |
Q-CAC3 |
Q-QPP6 |
Coronary Artery Disease (CAD): Antiplatelet Therapy |
Reported |
None |
None |
0.8701 |
None |
1520 |
0 |
1758 |
0 |
0.8646 |
0 |
N/A |
PY4 |
DMPH |
Salinas Valley Memorial Healthcare System |
Q-CAC4 |
Q-CMS135 |
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
Reported |
None |
None |
0.791 |
None |
193 |
0 |
247 |
0 |
0.7814 |
0 |
N/A |
PY4 |
DMPH |
Salinas Valley Memorial Healthcare System |
Q-CC1 |
Q-TRC |
Transitions of Care (TRC) |
Reported |
None |
None |
0.44 |
None |
102 |
0 |
293 |
0 |
0.3481 |
0 |
N/A |
PY4 |
DMPH |
Salinas Valley Memorial Healthcare System |
Q-PC11 |
Q-CMS69 |
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan |
Reported |
None |
None |
0.4955 |
None |
3910 |
0 |
13768 |
0 |
0.284 |
0 |
N/A |
PY4 |
DMPH |
Salinas Valley Memorial Healthcare System |
Q-PC12 |
Q-CMS147 |
Preventive Care and Screening: Influenza Immunization |
Reported |
None |
None |
0.4784 |
None |
8020 |
0 |
17755 |
0 |
0.4517 |
0 |
N/A |
PY4 |
DMPH |
Salinas Valley Memorial Healthcare System |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.5004 |
None |
1695 |
0 |
13155 |
0 |
0.1288 |
0 |
N/A |
PY4 |
DMPH |
Salinas Valley Memorial Healthcare System |
Q-PC7 |
Q-DEV |
Developmental Screening in the First Three Years of Life |
Reported |
None |
None |
0.2257 |
None |
63 |
0 |
300 |
0 |
0.21 |
0 |
N/A |
PY4 |
DMPH |
San Bernardino Mountains Community Hospital |
Q-PC11 |
Q-CMS69 |
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan |
Reported |
None |
None |
0.6847 |
None |
1023 |
0 |
1556 |
0 |
0.6575 |
0 |
N/A |
PY4 |
DMPH |
San Bernardino Mountains Community Hospital |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.5568 |
None |
758 |
0 |
1461 |
0 |
0.5188 |
0 |
N/A |
PY4 |
DPH |
San Francisco General Hospital |
Q-CAC2 |
Q-QPP118 |
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVSD < 40%) |
Reported |
None |
None |
0.8855 |
None |
790 |
0 |
896 |
0 |
0.8817 |
0 |
N/A |
PY4 |
DPH |
San Francisco General Hospital |
Q-CAC3 |
Q-QPP6 |
Coronary Artery Disease (CAD): Antiplatelet Therapy |
Reported |
None |
None |
0.8684 |
None |
1615 |
0 |
1872 |
0 |
0.8627 |
0 |
N/A |
PY4 |
DPH |
San Francisco General Hospital |
Q-CAC4 |
Q-CMS135 |
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
Reported |
None |
None |
0.8775 |
None |
714 |
0 |
794 |
0 |
0.8992 |
0 |
N/A |
PY4 |
DPH |
San Francisco General Hospital |
Q-CAD3 |
Q-KED |
Kidney Health Evaluation for Patients with Diabetes |
Reported |
None |
None |
0.4676 |
None |
2267 |
0 |
3514 |
0 |
0.6451 |
0 |
N/A |
PY4 |
DPH |
San Francisco General Hospital |
Q-IHE1 |
Q-IHE1 |
Breast Cancer Screening (BCS) - -Black/African American |
Reported |
None |
None |
0.4807 |
None |
395 |
0 |
908 |
0 |
0.435 |
0 |
N/A |
PY4 |
DPH |
San Francisco General Hospital |
Q-IHE1 |
Q-IHE1 |
Improving Health Equity 1Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
San Francisco General Hospital |
Q-IHE2 |
Q-IHE2 |
Controlling High Blood Pressure (CBP) - -Black/African American |
Reported |
None |
None |
0.5252 |
None |
658 |
0 |
1292 |
0 |
0.5093 |
0 |
N/A |
PY4 |
DPH |
San Francisco General Hospital |
Q-IHE2 |
Q-IHE2 |
Improving Health Equity 2Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
San Francisco General Hospital |
Q-MPH6 |
Q-PRS-E |
Prenatal Immunization Status |
Reported |
None |
None |
0.4576 |
None |
182 |
0 |
335 |
0 |
0.5433 |
0 |
N/A |
PY4 |
DPH |
San Francisco General Hospital |
Q-OA3 |
Q-QPP415 |
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older |
Reported |
None |
None |
0.8959 |
None |
343 |
0 |
384 |
0 |
0.8932 |
0 |
N/A |
PY4 |
DPH |
San Francisco General Hospital |
Q-OA4 |
Q-LBP |
Use of Imaging Studies for Low Back Pain (LBP) |
Reported |
None |
None |
0.8282 |
None |
400 |
0 |
474 |
0 |
0.8439 |
0 |
N/A |
PY4 |
DPH |
San Francisco General Hospital |
Q-PC12 |
Q-CMS147 |
Preventive Care and Screening: Influenza Immunization |
Reported |
None |
None |
0.7066 |
None |
17571 |
0 |
24914 |
0 |
0.7053 |
0 |
N/A |
PY4 |
DPH |
San Francisco General Hospital |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.6401 |
None |
11994 |
0 |
19616 |
0 |
0.6114 |
0 |
N/A |
PY4 |
DPH |
San Francisco General Hospital |
Q-CAD1 |
Q-HBD |
Comprehensive Diabetes Care: HbA1c Poor Control (>9.0%) (CDC-H9)* |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
San Francisco General Hospital |
Q-CAD1 |
Q-HBD |
Black/African-American |
Reported |
None |
None |
0.3406 |
None |
230 |
0 |
739 |
0 |
0.3112 |
0 |
N/A |
PY4 |
DPH |
San Francisco General Hospital |
Q-CAD1 |
Q-HBD |
Hispanic/Latino |
Reported |
None |
None |
0.3619 |
None |
369 |
0 |
1013 |
0 |
0.3643 |
0 |
N/A |
PY4 |
DPH |
San Francisco General Hospital |
Q-CAD1 |
Q-HBD |
Total Population |
Reported |
None |
None |
0.3406 |
None |
1005 |
0 |
3429 |
0 |
0.2931 |
0 |
N/A |
PY4 |
DMPH |
San Gorgonio Memorial Hospital |
Q-CAC2 |
Q-QPP118 |
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVSD < 40%) |
Reported |
None |
None |
0.8331 |
None |
28 |
0 |
34 |
0 |
0.8235 |
0 |
N/A |
PY4 |
DMPH |
San Gorgonio Memorial Hospital |
Q-OA3 |
Q-QPP415 |
Emergency Medicine: Emergency Department Utilization of CT for Minor Blunt Head Trauma for Patients Aged 18 Years and Older |
Reported |
None |
None |
0.9199 |
None |
82 |
0 |
87 |
0 |
0.9425 |
0 |
N/A |
PY4 |
DMPH |
San Gorgonio Memorial Hospital |
Q-PS1 |
Q-STK-2 |
Discharged on Antithrombotic Therapy |
Reported |
None |
None |
1 |
None |
31 |
0 |
31 |
0 |
1 |
0 |
N/A |
PY4 |
DPH |
San Joaquin General Hospital |
Q-BH3 |
Q-FUA |
30 Days |
Reported |
None |
None |
0.2878 |
None |
38 |
0 |
134 |
0 |
0.2836 |
0 |
N/A |
PY4 |
DPH |
San Joaquin General Hospital |
Q-BH3 |
Q-FUA |
7 Days |
Reported |
None |
None |
0.1304 |
None |
16 |
0 |
134 |
0 |
0.1194 |
0 |
N/A |
PY4 |
DPH |
San Joaquin General Hospital |
Q-BH3 |
Q-FUA |
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DPH |
San Joaquin General Hospital |
Q-CAC3 |
Q-QPP6 |
Coronary Artery Disease (CAD): Antiplatelet Therapy |
Reported |
None |
None |
0.8109 |
None |
810 |
0 |
1014 |
0 |
0.7988 |
0 |
N/A |
PY4 |
DPH |
San Joaquin General Hospital |
Q-IHE1 |
Q-IHE1 |
Asthma Medication Ratio (AMR) - -White |
Reported |
None |
None |
0.5989 |
None |
42 |
0 |
82 |
0 |
0.5122 |
0 |
N/A |
PY4 |
DPH |
San Joaquin General Hospital |
Q-IHE1 |
Q-IHE1 |
Improving Health Equity 1Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
San Joaquin General Hospital |
Q-IHE2 |
Q-IHE2 |
Improving Health Equity 2Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
San Joaquin General Hospital |
Q-IHE2 |
Q-IHE2 |
Prenatal and Postpartum Care: Postpartum Care (PPC-PST) - -Black/African American |
Reported |
None |
None |
0.7111 |
None |
38 |
0 |
76 |
0 |
0.5 |
0 |
N/A |
PY4 |
DPH |
San Joaquin General Hospital |
Q-OA4 |
Q-LBP |
Use of Imaging Studies for Low Back Pain (LBP) |
Reported |
None |
None |
0.7133 |
None |
204 |
0 |
1067 |
0 |
0.1912 |
0 |
N/A |
PY4 |
DPH |
San Joaquin General Hospital |
Q-PC11 |
Q-CMS69 |
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan |
Reported |
None |
None |
0.4955 |
None |
3164 |
0 |
14866 |
0 |
0.2128 |
0 |
N/A |
PY4 |
DPH |
San Joaquin General Hospital |
Q-PC12 |
Q-CMS147 |
Preventive Care and Screening: Influenza Immunization |
Reported |
None |
None |
0.4982 |
None |
9941 |
0 |
20982 |
0 |
0.4738 |
0 |
N/A |
PY4 |
DPH |
San Joaquin General Hospital |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.5004 |
None |
7002 |
0 |
18500 |
0 |
0.3785 |
0 |
N/A |
PY4 |
DPH |
San Joaquin General Hospital |
Q-CAD1 |
Q-HBD |
Comprehensive Diabetes Care: HbA1c Poor Control (>9.0%) (CDC-H9)* |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
San Joaquin General Hospital |
Q-CAD1 |
Q-HBD |
Black/African-American |
Reported |
None |
None |
0.4799 |
None |
107 |
0 |
216 |
0 |
0.4954 |
0 |
N/A |
PY4 |
DPH |
San Joaquin General Hospital |
Q-CAD1 |
Q-HBD |
Hispanic/Latino |
Reported |
None |
None |
0.4828 |
None |
178 |
0 |
357 |
0 |
0.4986 |
0 |
N/A |
PY4 |
DPH |
San Joaquin General Hospital |
Q-CAD1 |
Q-HBD |
Total Population |
Reported |
None |
None |
0.4285 |
None |
764 |
0 |
1743 |
0 |
0.4383 |
0 |
N/A |
PY4 |
DPH |
San Mateo Medical Center |
Q-CAC2 |
Q-QPP118 |
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVSD < 40% |
Reported |
None |
None |
0.8589 |
None |
242 |
0 |
284 |
0 |
0.8521 |
0 |
N/A |
PY4 |
DPH |
San Mateo Medical Center |
Q-CAC3 |
Q-QPP6 |
Coronary Artery Disease (CAD): Antiplatelet Therapy |
Reported |
None |
None |
0.9199 |
None |
531 |
0 |
555 |
0 |
0.9568 |
0 |
N/A |
PY4 |
DPH |
San Mateo Medical Center |
Q-CAC4 |
Q-CMS135 |
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
Reported |
None |
None |
0.8554 |
None |
29 |
0 |
34 |
0 |
0.8529 |
0 |
N/A |
PY4 |
DPH |
San Mateo Medical Center |
Q-CC2 |
Q-PCR |
Plan All-Cause Readmissions (PCR) |
Reported |
None |
None |
0 |
None |
12 |
0 |
None |
4 |
None |
4 |
N/A |
PY4 |
DPH |
San Mateo Medical Center |
Q-IHE1 |
Q-IHE1 |
Improving Health Equity 1Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
San Mateo Medical Center |
Q-IHE2 |
Q-IHE1 |
Breast Cancer Screening (BCS) - -Black/African American |
Reported |
None |
None |
0.5921 |
None |
27 |
0 |
46 |
0 |
0.587 |
0 |
N/A |
PY4 |
DPH |
San Mateo Medical Center |
Q-IHE2 |
Q-IHE2 |
Improving Health Equity 2Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
San Mateo Medical Center |
Q-IHE2 |
Q-IHE2 |
Preventative Care and Screening: Tobacco Use - Screening and Cessation Intervention - Rate 1 (informational only) -Black/African American |
Reported |
None |
None |
0 |
None |
359 |
0 |
363 |
0 |
0.989 |
0 |
N/A |
PY4 |
DPH |
San Mateo Medical Center |
Q-IHE2 |
Q-IHE2 |
Preventative Care and Screening: Tobacco Use - Screening and Cessation Intervention - Rate 2 -Black/African American |
Reported |
None |
None |
0.6395 |
None |
73 |
0 |
120 |
0 |
0.6083 |
0 |
N/A |
PY4 |
DPH |
San Mateo Medical Center |
Q-IHE2 |
Q-IHE2 |
Preventative Care and Screening: Tobacco Use - Screening and Cessation Intervention - Rate 3 -Black/African American |
Reported |
None |
None |
0.8688 |
None |
312 |
0 |
363 |
0 |
0.8595 |
0 |
N/A |
PY4 |
DPH |
San Mateo Medical Center |
Q-MPH6 |
Q-PRS-E |
Prenatal Immunization Status |
Reported |
None |
None |
0.4576 |
None |
50 |
0 |
90 |
0 |
0.5556 |
0 |
N/A |
PY4 |
DPH |
San Mateo Medical Center |
Q-OA4 |
Q-LBP |
Use of Imaging Studies for Low Back Pain (LBP) |
Reported |
None |
None |
0.8282 |
None |
161 |
0 |
177 |
0 |
0.9096 |
0 |
N/A |
PY4 |
DPH |
San Mateo Medical Center |
Q-PC11 |
Q-CMS69 |
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan |
Reported |
None |
None |
0.4955 |
None |
5240 |
0 |
16881 |
0 |
0.3104 |
0 |
N/A |
PY4 |
DPH |
San Mateo Medical Center |
Q-PC12 |
Q-CMS147 |
Preventive Care and Screening: Influenza Immunization |
Reported |
None |
None |
0.6514 |
None |
8630 |
0 |
13401 |
0 |
0.644 |
0 |
N/A |
PY4 |
DPH |
San Mateo Medical Center |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.6194 |
None |
12634 |
0 |
21471 |
0 |
0.5884 |
0 |
N/A |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-BH3 |
Q-FUA |
30 Days |
Reported |
None |
None |
0.2436 |
None |
98 |
0 |
418 |
0 |
0.2344 |
0 |
N/A |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-BH3 |
Q-FUA |
7 Days |
Reported |
None |
None |
0.1113 |
None |
41 |
0 |
418 |
0 |
0.0981 |
0 |
N/A |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-BH3 |
Q-FUA |
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-BH5 |
Q-FUI |
30 Days |
Reported |
None |
None |
0.3979 |
None |
62 |
0 |
169 |
0 |
0.3669 |
0 |
N/A |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-BH5 |
Q-FUI |
7 Days |
Reported |
None |
None |
0.3793 |
None |
62 |
0 |
169 |
0 |
0.3669 |
0 |
N/A |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-BH5 |
Q-FUI |
Follow-Up After High-Intensity Care for Substance Use Disorder (FUI)* |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-CAC5 |
Q-CMS347 |
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease |
Reported |
None |
None |
0.6991 |
None |
4352 |
0 |
6366 |
0 |
0.6836 |
0 |
N/A |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-CAD3 |
Q-KED |
Kidney Health Evaluation for Patients with Diabetes |
Reported |
None |
None |
0.4676 |
None |
3268 |
0 |
6761 |
0 |
0.4834 |
0 |
N/A |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-CAR2 |
Q-PCE |
Bronchodilator |
Reported |
None |
None |
0.8424 |
None |
66 |
0 |
79 |
0 |
0.8354 |
0 |
N/A |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-CAR2 |
Q-PCE |
Pharmacotherapy Management of COPD Exacerbation (PCE) |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-CAR2 |
Q-PCE |
Systemic Corticosteroid |
Reported |
None |
None |
0.6391 |
None |
49 |
0 |
79 |
0 |
0.6203 |
0 |
N/A |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-IHE1 |
Q-IHE1 |
Prenatal and Postpartum Care: Postpartum Care (PPC-PST) - -Black/African American |
Reported |
None |
None |
0.7111 |
None |
39 |
0 |
59 |
0 |
0.661 |
0 |
N/A |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-IHE1 |
Q-IHE1 |
Improving Health Equity 1Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-IHE2 |
Q-IHE2 |
Colorectal Cancer Screening - -Black/African American |
Reported |
None |
None |
0.5241 |
None |
542 |
0 |
1052 |
0 |
0.5152 |
0 |
N/A |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-IHE2 |
Q-IHE2 |
Improving Health Equity 2Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-MPH1 |
Q-PC02 |
Cesarean Birth (PC02-CH) |
Reported |
None |
None |
0.22 |
None |
198 |
0 |
974 |
0 |
0.2033 |
0 |
N/A |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-MPH6 |
Q-PRS-E |
Prenatal Immunization Status |
Reported |
None |
None |
0.4576 |
None |
479 |
0 |
837 |
0 |
0.5723 |
0 |
N/A |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-OA1 |
Q-URI |
Appropriate Treatment for Upper Respiratory Infection (URI) |
Reported |
None |
None |
0.9434 |
None |
2215 |
0 |
2265 |
0 |
0.9779 |
0 |
N/A |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-OA2 |
Q-AAB |
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB) |
Reported |
None |
None |
0.7039 |
None |
64 |
0 |
81 |
0 |
0.7901 |
0 |
N/A |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-PC12 |
Q-CMS147 |
Preventive Care and Screening: Influenza Immunization |
Reported |
None |
None |
0.5184 |
None |
24209 |
0 |
48785 |
0 |
0.4962 |
0 |
N/A |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.5004 |
None |
10773 |
0 |
27343 |
0 |
0.394 |
0 |
N/A |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-CAD1 |
Q-HBD |
Comprehensive Diabetes Care: HbA1c Poor Control (>9.0%) (CDC-H9)* |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-CAD1 |
Q-HBD |
Black/African-American |
Reported |
None |
None |
0.3591 |
None |
151 |
0 |
418 |
0 |
0.3612 |
0 |
N/A |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-CAD1 |
Q-HBD |
Hispanic/Latino |
Reported |
None |
None |
0.4139 |
None |
1195 |
0 |
2832 |
0 |
0.422 |
0 |
N/A |
PY4 |
DPH |
Santa Clara Valley Medical Center |
Q-CAD1 |
Q-HBD |
Total Population |
Reported |
None |
None |
0.3424 |
None |
2297 |
0 |
6705 |
0 |
0.3426 |
0 |
N/A |
PY4 |
DMPH |
Seneca Healthcare District |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.5004 |
None |
0 |
0 |
228 |
0 |
0 |
0 |
N/A |
PY4 |
DMPH |
Sierra View District Hospital |
Q-PC12 |
Q-CMS147 |
Preventive Care and Screening: Influenza Immunization |
Reported |
None |
None |
0.2671 |
None |
257 |
0 |
4570 |
0 |
0.0562 |
0 |
N/A |
PY4 |
DMPH |
Sonoma Valley Hospital |
Q-PS4 |
Q-CDI |
Reduction in Hospital Acquired Clostridium Difficile Infections |
Reported |
None |
None |
0Â |
None |
None |
1 |
None |
1 |
None |
1 |
N/A |
PY4 |
DMPH |
Sonoma Valley Hospital |
Q-PS5 |
Q-SSI |
Surgical Site Infection (SSI)Â |
Reported |
None |
None |
0Â |
None |
0 |
0 |
None |
1 |
None |
1 |
N/A |
PY4 |
DMPH |
Southern Inyo Hospital |
Q-PC1 |
Q-BCS |
Breast Cancer Screening (BCS) |
None |
None |
None |
N/A |
3 |
None |
1 |
None |
4 |
None |
1 |
N/A |
PY4 |
DMPH |
Southern Inyo Hospital |
Q-PC3 |
Q-WCV |
Child and Adolescent Well Care Visits |
None |
None |
None |
0.5433 |
None |
100 |
0 |
187 |
0 |
0.5348 |
0 |
N/A |
PY4 |
DMPH |
Surprise Valley |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.5004 |
None |
0 |
0 |
30 |
0 |
0 |
0 |
N/A |
PY4 |
DMPH |
Tahoe Forest Hospital District |
Q-BH3 |
Q-FUA |
30 Days |
Reported |
None |
None |
0.3058 |
None |
17 |
0 |
56 |
0 |
0.3036 |
0 |
N/A |
PY4 |
DMPH |
Tahoe Forest Hospital District |
Q-BH3 |
Q-FUA |
7 Days |
Reported |
None |
None |
0.2159 |
None |
12 |
0 |
56 |
0 |
0.2143 |
0 |
N/A |
PY4 |
DMPH |
Tahoe Forest Hospital District |
Q-BH3 |
Q-FUA |
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DMPH |
Tahoe Forest Hospital District |
Q-CC1 |
Q-TRC |
Transitions of Care (TRC) |
Reported |
None |
None |
0.5897 |
None |
58 |
0 |
102 |
0 |
0.5686 |
0 |
N/A |
PY4 |
DMPH |
Tahoe Forest Hospital District |
Q-PC1 |
Q-BCS |
Breast Cancer Screening (BCS) |
Reported |
None |
None |
0.622 |
None |
80 |
0 |
129 |
0 |
0.6202 |
0 |
N/A |
PY4 |
DMPH |
Tahoe Forest Hospital District |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.5004 |
None |
664 |
0 |
1583 |
0 |
0.4195 |
0 |
N/A |
PY4 |
DMPH |
Tahoe Forest Hospital District |
Q-PC9 |
Q-IMA |
Immunizations for Adolescents |
Reported |
None |
None |
0.309 |
None |
22 |
0 |
89 |
0 |
0.2472 |
0 |
N/A |
PY4 |
DMPH |
Tahoe Forest Hospital District |
Q-PS4 |
Q-CDI |
Reduction in Hospital Acquired Clostridium Difficile Infections |
Reported |
None |
None |
0 |
None |
None |
1 |
None |
1 |
None |
1 |
N/A |
PY4 |
DMPH |
Tahoe Forest Hospital District |
Q-CAD1 |
Q-HBD |
Comprehensive Diabetes Care: HbA1c Poor Control (>9.0%) (CDC-H9)* |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DMPH |
Tahoe Forest Hospital District |
Q-CAD1 |
Q-HBD |
Black/African-American |
Reported |
None |
None |
N/A |
3 |
0 |
0 |
0 |
0 |
0 |
0 |
N/A |
PY4 |
DMPH |
Tahoe Forest Hospital District |
Q-CAD1 |
Q-HBD |
Hispanic/Latino |
Reported |
None |
None |
0.3406 |
None |
None |
1 |
30 |
0 |
None |
1 |
N/A |
PY4 |
DMPH |
Tahoe Forest Hospital District |
Q-CAD1 |
Q-HBD |
Total Population |
Reported |
None |
None |
0.3406 |
None |
12 |
0 |
55 |
0 |
0.2182 |
0 |
N/A |
PY4 |
DMPH |
Tri-City Medical Center |
Q-BH1 |
Q-COB |
Concurrent Use of Opioids and Benzodiazepines (COB-AD) |
Reported |
None |
None |
N/A |
3 |
0 |
0 |
0 |
0 |
0 |
0 |
N/A |
PY4 |
DMPH |
Tri-City Medical Center |
Q-BH4 |
Q-OHD |
Use of Opioids at High Dosage in Persons Without Cancer (OHD-AD) |
Reported |
None |
None |
N/A |
3 |
0 |
0 |
0 |
0 |
0 |
0 |
N/A |
PY4 |
DMPH |
Tri-City Medical Center |
Q-BH5 |
Q-FUI |
30 Days |
Reported |
None |
None |
0.3894 |
None |
None |
1 |
124 |
0 |
None |
1 |
N/A |
PY4 |
DMPH |
Tri-City Medical Center |
Q-BH5 |
Q-FUI |
7 Days |
Reported |
None |
None |
0.234 |
None |
None |
1 |
124 |
0 |
None |
1 |
N/A |
PY4 |
DMPH |
Tri-City Medical Center |
Q-BH5 |
Q-FUI |
Follow-Up After High-Intensity Care for Substance Use Disorder (FUI)* |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DMPH |
Tri-City Medical Center |
Q-BH6 |
Q-POD |
Pharmacotherapy for Opioid Use Disorder* |
Reported |
None |
None |
N/A |
3 |
0 |
0 |
0 |
0 |
0 |
0 |
N/A |
PY4 |
DMPH |
Tri-City Medical Center |
Q-CAC4 |
Q-CMS135 |
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
Reported |
None |
None |
N/A |
3 |
0 |
0 |
0 |
0 |
0 |
0 |
N/A |
PY4 |
DMPH |
Tri-City Medical Center |
Q-EC1 |
Q-QPP47 |
Advance Care Plan |
Reported |
None |
None |
N/A |
3 |
0 |
0 |
0 |
0 |
0 |
0 |
N/A |
PY4 |
DMPH |
Tri-City Medical Center |
Q-MPH6 |
Q-PRS-E |
Prenatal Immunization Status |
Reported |
None |
None |
0.1696 |
None |
None |
1 |
533 |
0 |
None |
1 |
N/A |
PY4 |
DMPH |
Tri-City Medical Center |
Q-PC12 |
Q-CMS147 |
Preventive Care and Screening: Influenza Immunization |
Reported |
None |
None |
0.7182 |
None |
2129 |
0 |
2414 |
0 |
0.8819 |
0 |
N/A |
PY4 |
DMPH |
Tri-City Medical Center |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.5004 |
None |
252 |
0 |
11730 |
0 |
0.0215 |
0 |
N/A |
PY4 |
DMPH |
Tri-City Medical Center |
Q-PC14 |
Q-CMS138 |
Preventative Care and Screening: Tobacco Use - Screening and Cessation Intervention |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DMPH |
Tri-City Medical Center |
Q-PC14 |
Q-CMS138 |
Rate 1 (informational only) |
Reported |
None |
None |
0 |
None |
3363 |
0 |
3544 |
0 |
0.9489 |
0 |
N/A |
PY4 |
DMPH |
Tri-City Medical Center |
Q-PC14 |
Q-CMS138 |
Rate 2 |
Reported |
None |
None |
0.1093 |
None |
24 |
0 |
1251 |
0 |
0.0192 |
0 |
N/A |
PY4 |
DMPH |
Tri-City Medical Center |
Q-PC14 |
Q-CMS138 |
Rate 3 |
Reported |
None |
None |
0.7542 |
None |
24 |
0 |
3544 |
0 |
0.0068 |
0 |
N/A |
PY4 |
DMPH |
Trinity Hospital |
Q-PC3 |
Q-WCV |
Child and Adolescent Well Care Visits |
Reported |
None |
None |
0.3941Â |
None |
185 |
0 |
614 |
0 |
0.3013Â |
0 |
N/A |
PY4 |
DPH |
UC Davis Medical Center |
Q-CAC2 |
Q-QPP118 |
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVSD < 40%) |
Reported |
None |
None |
0.8249 |
None |
763 |
0 |
937 |
0 |
0.8143 |
0 |
N/A |
PY4 |
DPH |
UC Davis Medical Center |
Q-CC2 |
Q-PCR |
Plan All-Cause Readmissions (PCR) |
Reported |
None |
None |
0 |
None |
15 |
0 |
None |
4 |
None |
4 |
N/A |
PY4 |
DPH |
UC Davis Medical Center |
Q-IHE1 |
Q-IHE1 |
Controlling High Blood Pressure (CBP) - -Black/African American |
Reported |
None |
None |
0.586 |
None |
30 |
0 |
52 |
0 |
0.5769 |
0 |
N/A |
PY4 |
DPH |
UC Davis Medical Center |
Q-IHE1 |
Q-IHE1 |
Improving Health Equity 1Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
UC Davis Medical Center |
Q-IHE2 |
Q-IHE2 |
Exclusive Breast Milk Feeding (PC-05) - -Black/African American |
Reported |
None |
None |
0.4776 |
None |
32 |
0 |
75 |
0 |
0.4267 |
0 |
N/A |
PY4 |
DPH |
UC Davis Medical Center |
Q-IHE2 |
Q-IHE2 |
Improving Health Equity 2Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
UC Davis Medical Center |
Q-MPH6 |
Q-PRS-E |
Prenatal Immunization Status |
Reported |
None |
None |
0.4576 |
None |
28 |
0 |
51 |
0 |
0.549 |
0 |
N/A |
PY4 |
DPH |
UC Davis Medical Center |
Q-OA4 |
Q-LBP |
Use of Imaging Studies for Low Back Pain (LBP) |
Reported |
None |
None |
0.8282 |
None |
76 |
0 |
90 |
0 |
0.8444 |
0 |
N/A |
PY4 |
DPH |
UC Davis Medical Center |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.5079 |
None |
2139 |
0 |
4605 |
0 |
0.4645 |
0 |
N/A |
PY4 |
DPH |
UC Davis Medical Center |
Q-PS1 |
Q-STK-2 |
Discharged on Antithrombotic Therapy |
Reported |
None |
None |
0.9918 |
None |
309 |
0 |
332 |
0 |
0.9307 |
0 |
N/A |
PY4 |
DPH |
UC Davis Medical Center |
Q-CAD1 |
Q-HBD |
Comprehensive Diabetes Care: HbA1c Poor Control (>9.0%) (CDC-H9)* |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
UC Davis Medical Center |
Q-CAD1 |
Q-HBD |
Black/African-American |
Reported |
None |
None |
0.3886 |
None |
26 |
0 |
66 |
0 |
0.3939 |
0 |
N/A |
PY4 |
DPH |
UC Davis Medical Center |
Q-CAD1 |
Q-HBD |
Hispanic/Latino |
Reported |
None |
None |
0.3941 |
None |
30 |
0 |
75 |
0 |
0.4 |
0 |
N/A |
PY4 |
DPH |
UC Davis Medical Center |
Q-CAD1 |
Q-HBD |
Total Population |
Reported |
None |
None |
0.3406 |
None |
94 |
0 |
283 |
0 |
0.3322 |
0 |
N/A |
PY4 |
DPH |
UC Irvine Medical Center |
Q-BH3 |
Q-FUA |
30 Days |
Reported |
None |
None |
0.1539 |
None |
12 |
0 |
89 |
0 |
0.1348 |
0 |
N/A |
PY4 |
DPH |
UC Irvine Medical Center |
Q-BH3 |
Q-FUA |
7 Days |
Reported |
None |
None |
0.0938 |
None |
None |
1 |
89 |
0 |
None |
1 |
N/A |
PY4 |
DPH |
UC Irvine Medical Center |
Q-BH3 |
Q-FUA |
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DPH |
UC Irvine Medical Center |
Q-CAC2 |
Q-QPP118 |
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVSD < 40%) |
Reported |
None |
None |
0.8364 |
None |
914 |
0 |
1105 |
0 |
0.8271 |
0 |
N/A |
PY4 |
DPH |
UC Irvine Medical Center |
Q-CAC3 |
Q-QPP6 |
Coronary Artery Disease (CAD): Antiplatelet Therapy |
Reported |
None |
None |
0.854 |
None |
1745 |
0 |
2061 |
0 |
0.8467 |
0 |
N/A |
PY4 |
DPH |
UC Irvine Medical Center |
Q-CAC4 |
Q-CMS135 |
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
Reported |
None |
None |
0.8408 |
None |
415 |
0 |
496 |
0 |
0.8367 |
0 |
N/A |
PY4 |
DPH |
UC Irvine Medical Center |
Q-CAC5 |
Q-CMS347 |
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease |
Reported |
None |
None |
0.7357 |
None |
1261 |
0 |
1741 |
0 |
0.7243 |
0 |
N/A |
PY4 |
DPH |
UC Irvine Medical Center |
Q-CAD3 |
Q-KED |
Kidney Health Evaluation for Patients with Diabetes |
Reported |
None |
None |
0.4676 |
None |
783 |
0 |
1293 |
0 |
0.6056 |
0 |
N/A |
PY4 |
DPH |
UC Irvine Medical Center |
Q-CC2 |
Q-PCR |
Plan All-Cause Readmissions (PCR) |
Reported |
None |
None |
0 |
None |
34 |
0 |
41.0588 |
0 |
0.8281 |
0 |
N/A |
PY4 |
DPH |
UC Irvine Medical Center |
Q-MPH6 |
Q-PRS-E |
Prenatal Immunization Status |
Reported |
None |
None |
0.4576 |
None |
195 |
0 |
401 |
0 |
0.4863 |
0 |
N/A |
PY4 |
DPH |
UC Irvine Medical Center |
Q-OA4 |
Q-LBP |
Use of Imaging Studies for Low Back Pain (LBP) |
Reported |
None |
None |
0.8282 |
None |
465 |
0 |
498 |
0 |
0.9337 |
0 |
N/A |
PY4 |
DPH |
UC Irvine Medical Center |
Q-PC11 |
Q-CMS69 |
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan |
Reported |
None |
None |
0.4955 |
None |
5945 |
0 |
13478 |
0 |
0.4411 |
0 |
N/A |
PY4 |
DPH |
UC Irvine Medical Center |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.5916 |
None |
7787 |
0 |
13967 |
0 |
0.5575 |
0 |
N/A |
PY4 |
DPH |
UC Irvine Medical Center |
Q-PS1 |
Q-STK-2 |
Discharged on Antithrombotic Therapy |
Reported |
None |
None |
0.9918 |
None |
395 |
0 |
422 |
0 |
0.936 |
0 |
N/A |
PY4 |
DPH |
UC Irvine Medical Center |
Q-PS5 |
Q-SSI |
Surgical Site Infection (SSI) |
Reported |
None |
None |
0 |
None |
33 |
0 |
38.08 |
0 |
0.8666 |
0 |
N/A |
PY4 |
DPH |
UC Irvine Medical Center |
Q-CAD1 |
Q-HBD |
Comprehensive Diabetes Care: HbA1c Poor Control (>9.0%) (CDC-H9)* |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
UC Irvine Medical Center |
Q-CAD1 |
Q-HBD |
Black/African-American |
Reported |
None |
None |
0.3406 |
None |
None |
1 |
38 |
0 |
None |
1 |
N/A |
PY4 |
DPH |
UC Irvine Medical Center |
Q-CAD1 |
Q-HBD |
Hispanic/Latino |
Reported |
None |
None |
0.3406 |
None |
338 |
0 |
1051 |
0 |
0.3216 |
0 |
N/A |
PY4 |
DPH |
UC Irvine Medical Center |
Q-CAD1 |
Q-HBD |
Total Population |
Reported |
None |
None |
0.3406 |
None |
448 |
0 |
1400 |
0 |
0.32 |
0 |
N/A |
PY4 |
DPH |
UC Los Angeles Medical Center |
Q-CAC2 |
Q-QPP118 |
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVSD < 40%) |
Reported |
None |
None |
0.816 |
None |
1259 |
0 |
1565 |
0 |
0.8045 |
0 |
N/A |
PY4 |
DPH |
UC Los Angeles Medical Center |
Q-CAC4 |
Q-CMS135 |
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
Reported |
None |
None |
0.6969 |
None |
130 |
0 |
220 |
0 |
0.5909 |
0 |
N/A |
PY4 |
DPH |
UC Los Angeles Medical Center |
Q-CAD3 |
Q-KED |
Kidney Health Evaluation for Patients with Diabetes |
Reported |
None |
None |
0.4676 |
None |
22 |
0 |
46 |
0 |
0.4783 |
0 |
N/A |
PY4 |
DPH |
UC Los Angeles Medical Center |
Q-IHE1 |
Q-IHE1 |
Improving Health Equity 1Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
UC Los Angeles Medical Center |
Q-IHE2 |
Q-IHE1 |
Colorectal Cancer Screening - -Native Hawaiian/Pacific Islander |
Reported |
None |
None |
0.3059 |
None |
None |
1 |
33 |
0 |
None |
1 |
N/A |
PY4 |
DPH |
UC Los Angeles Medical Center |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.5004 |
None |
5355 |
0 |
27828 |
0 |
0.1924 |
0 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-BH1 |
Q-COB |
Concurrent Use of Opioids and Benzodiazepines (COB-AD) |
Reported |
None |
None |
0.1415 |
None |
21 |
0 |
109 |
0 |
0.1927 |
0 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-BH2 |
Q-DRR-E |
Depression Remission (Adolescents) - informational only |
Reported |
None |
None |
N/A |
3 |
0 |
0 |
0 |
0 |
0 |
0 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-BH2 |
Q-DRR-E |
Depression Response (Adolescents) - informational only |
Reported |
None |
None |
N/A |
3 |
0 |
0 |
0 |
0 |
0 |
0 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-BH2 |
Q-DRR-E |
Follow-Up PHQ-9 (Adolescents) - informational only |
Reported |
None |
None |
N/A |
3 |
0 |
0 |
0 |
0 |
0 |
0 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-BH2 |
Q-DRR-E |
Depression Remission (Adults) |
Reported |
None |
None |
N/A |
3 |
None |
1 |
None |
4 |
None |
1 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-BH2 |
Q-DRR-E |
Depression Response (Adults) |
Reported |
None |
None |
N/A |
3 |
None |
1 |
None |
4 |
None |
1 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-BH2 |
Q-DRR-E |
Follow-Up PHQ-9 (Adults) |
Reported |
None |
None |
N/A |
3 |
None |
1 |
None |
4 |
None |
1 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-BH2 |
Q-DRR-E |
Depression Remission or Response for Adolescents and Adults (DRR-E) |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DPH |
UC San Diego Medical Center |
Q-BH4 |
Q-OHD |
Use of Opioids at High Dosage in Persons Without Cancer (OHD-AD) |
Reported |
None |
None |
0.0397 |
None |
None |
1 |
95 |
0 |
None |
1 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-BH6 |
Q-POD |
Pharmacotherapy for Opioid Use Disorder* |
Reported |
None |
None |
N/A |
3 |
None |
1 |
None |
1 |
None |
1 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-CAC2 |
Q-QPP118 |
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVSD < 40%) |
Reported |
None |
None |
0.8095 |
None |
951 |
0 |
1193 |
0 |
0.7972 |
0 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-CAC3 |
Q-QPP6 |
Coronary Artery Disease (CAD): Antiplatelet Therapy |
Reported |
None |
None |
0.85 |
None |
2365 |
0 |
2808 |
0 |
0.8422 |
0 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-CAC4 |
Q-CMS135 |
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
Reported |
None |
None |
0.7772 |
None |
920 |
0 |
1201 |
0 |
0.766 |
0 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-CAD3 |
Q-KED |
Kidney Health Evaluation for Patients with Diabetes |
Reported |
None |
None |
0.4676 |
None |
103 |
0 |
179 |
0 |
0.5754 |
0 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-CAR2 |
Q-PCE |
Bronchodilator |
Reported |
None |
None |
N/A |
3 |
None |
1 |
None |
1 |
None |
1 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-CAR2 |
Q-PCE |
Pharmacotherapy Management of COPD Exacerbation (PCE) |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DPH |
UC San Diego Medical Center |
Q-CAR2 |
Q-PCE |
Systemic Corticosteroid |
Reported |
None |
None |
N/A |
3 |
None |
1 |
None |
1 |
None |
1 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-CC2 |
Q-PCR |
Plan All-Cause Readmissions (PCR) |
Reported |
None |
None |
0 |
None |
None |
1 |
None |
1 |
None |
1 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-IHE1 |
Q-IHE1 |
Child and Adolescent Well Care Visits - -Black/African American |
Reported |
None |
None |
0.3941 |
None |
13 |
0 |
36 |
0 |
0.3611 |
0 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-IHE1 |
Q-IHE1 |
Improving Health Equity 1Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
UC San Diego Medical Center |
Q-IHE2 |
Q-IHE2 |
HIV Viral Suppression (HVL-AD) - -Hispanic/Latino |
Reported |
None |
None |
0.776 |
None |
30 |
0 |
39 |
0 |
0.7692 |
0 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-IHE2 |
Q-IHE2 |
Improving Health Equity 2Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
UC San Diego Medical Center |
Q-PC10 |
Q-LSC |
Lead Screening in Children |
Reported |
None |
None |
0.6131 |
None |
94 |
0 |
164 |
0 |
0.5732 |
0 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-PC11 |
Q-CMS69 |
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan |
Reported |
None |
None |
0.5052 |
None |
1421 |
0 |
3102 |
0 |
0.4581 |
0 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.6869 |
None |
1527 |
0 |
2302 |
0 |
0.6633 |
0 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-CAD1 |
Q-HBD |
Comprehensive Diabetes Care: HbA1c Poor Control (>9.0%) (CDC-H9)* |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
UC San Diego Medical Center |
Q-CAD1 |
Q-HBD |
Black/African-American |
Reported |
None |
None |
N/A |
3 |
None |
1 |
None |
4 |
None |
1 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-CAD1 |
Q-HBD |
Hispanic/Latino |
Reported |
None |
None |
0.3406 |
None |
None |
1 |
38 |
0 |
None |
1 |
N/A |
PY4 |
DPH |
UC San Diego Medical Center |
Q-CAD1 |
Q-HBD |
Total Population |
Reported |
None |
None |
0.3406 |
None |
40 |
0 |
174 |
0 |
0.2299 |
0 |
N/A |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-BH1 |
Q-COB |
Concurrent Use of Opioids and Benzodiazepines (COB-AD) |
Reported |
None |
None |
0.1411 |
None |
51 |
0 |
346 |
0 |
0.1474 |
0 |
N/A |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-BH3 |
Q-FUA |
30 Days |
Reported |
None |
None |
0.2057 |
None |
None |
1 |
52 |
0 |
None |
1 |
N/A |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-BH3 |
Q-FUA |
7 Days |
Reported |
None |
None |
0.0749 |
None |
None |
1 |
52 |
0 |
None |
1 |
N/A |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-BH3 |
Q-FUA |
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-CAC2 |
Q-QPP118 |
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVSD < 40%) |
Reported |
None |
None |
0.8313 |
None |
874 |
0 |
1064 |
0 |
0.8214 |
0 |
N/A |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-CAC4 |
Q-CMS135 |
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
Reported |
None |
None |
0.8572 |
None |
554 |
0 |
648 |
0 |
0.8549 |
0 |
N/A |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-CAD3 |
Q-KED |
Kidney Health Evaluation for Patients with Diabetes |
Reported |
None |
None |
0.4676 |
None |
494 |
0 |
818 |
0 |
0.6039 |
0 |
N/A |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-CAR2 |
Q-PCE |
Bronchodilator |
Reported |
None |
None |
0.9057 |
None |
39 |
0 |
43 |
0 |
0.907 |
0 |
N/A |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-CAR2 |
Q-PCE |
Pharmacotherapy Management of COPD Exacerbation (PCE) |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-CAR2 |
Q-PCE |
Systemic Corticosteroid |
Reported |
None |
None |
0.636 |
None |
25 |
0 |
43 |
0 |
0.5814 |
0 |
N/A |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-IHE1 |
Q-IHE1 |
Improving Health Equity 1Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-IHE2 |
Q-IHE1 |
Controlling High Blood Pressure (CBP) - -Black/African American |
Reported |
None |
None |
0.5601 |
None |
131 |
0 |
239 |
0 |
0.5481 |
0 |
N/A |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-OA4 |
Q-LBP |
Use of Imaging Studies for Low Back Pain (LBP) |
Reported |
None |
None |
0.8216 |
None |
362 |
0 |
441 |
0 |
0.8209 |
0 |
N/A |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-PC10 |
Q-LSC |
Lead Screening in Children |
Reported |
None |
None |
0.6131 |
None |
118 |
0 |
258 |
0 |
0.4574 |
0 |
N/A |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-PC12 |
Q-CMS147 |
Preventive Care and Screening: Influenza Immunization |
Reported |
None |
None |
0.6462 |
None |
20067 |
0 |
31444 |
0 |
0.6382 |
0 |
N/A |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.6049 |
None |
4033 |
0 |
7048 |
0 |
0.5722 |
0 |
N/A |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-PC15 |
Q-WCC |
BMI |
Reported |
None |
None |
0.8718 |
None |
2342 |
0 |
2585 |
0 |
0.906 |
0 |
N/A |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-PC15 |
Q-WCC |
Counseling for Nutrition |
Reported |
None |
None |
0.6409 |
None |
1604 |
0 |
2585 |
0 |
0.6205 |
0 |
N/A |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-PC15 |
Q-WCC |
Counseling for Physical Activity |
Reported |
None |
None |
0.6249 |
None |
1567 |
0 |
2585 |
0 |
0.6062 |
0 |
N/A |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-PC15 |
Q-WCC |
Weight Assessment & Counseling for Nutrition and Physical Activity for Children & Adolescents |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-CAD1 |
Q-HBD |
Comprehensive Diabetes Care: HbA1c Poor Control (>9.0%) (CDC-H9)* |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-CAD1 |
Q-HBD |
Black/African-American |
Reported |
None |
None |
0.3406 |
None |
51 |
0 |
173 |
0 |
0.2948 |
0 |
N/A |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-CAD1 |
Q-HBD |
Hispanic/Latino |
Reported |
None |
None |
0.3406 |
None |
32 |
0 |
113 |
0 |
0.2832 |
0 |
N/A |
PY4 |
DPH |
UC San Francisco Medical Center |
Q-CAD1 |
Q-HBD |
Total Population |
Reported |
None |
None |
0.3406 |
None |
202 |
0 |
816 |
0 |
0.2475 |
0 |
N/A |
PY4 |
DPH |
Ventura County Medical Center |
Q-BH1 |
Q-COB |
Concurrent Use of Opioids and Benzodiazepines (COB-AD) |
Reported |
None |
None |
0.1187 |
None |
127 |
0 |
1037 |
0 |
0.1225 |
0 |
N/A |
PY4 |
DPH |
Ventura County Medical Center |
Q-BH3 |
Q-FUA |
30 Days |
Reported |
None |
None |
0.214 |
None |
52 |
0 |
258 |
0 |
0.2016 |
0 |
N/A |
PY4 |
DPH |
Ventura County Medical Center |
Q-BH3 |
Q-FUA |
7 Days |
Reported |
None |
None |
0.1172 |
None |
27 |
0 |
258 |
0 |
0.1047 |
0 |
N/A |
PY4 |
DPH |
Ventura County Medical Center |
Q-BH3 |
Q-FUA |
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DPH |
Ventura County Medical Center |
Q-BH4 |
Q-OHD |
Use of Opioids at High Dosage in Persons Without Cancer (OHD-AD) |
Reported |
None |
None |
0.0337 |
None |
30 |
0 |
870 |
0 |
0.0345 |
0 |
N/A |
PY4 |
DPH |
Ventura County Medical Center |
Q-CAC2 |
Q-QPP118 |
Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVSD < 40%) |
Reported |
None |
None |
0.8353 |
None |
370 |
0 |
448 |
0 |
0.8259 |
0 |
N/A |
PY4 |
DPH |
Ventura County Medical Center |
Q-CAC3 |
Q-QPP6 |
Coronary Artery Disease (CAD): Antiplatelet Therapy |
Reported |
None |
None |
0.9199 |
None |
815 |
0 |
879 |
0 |
0.9272 |
0 |
N/A |
PY4 |
DPH |
Ventura County Medical Center |
Q-CAC4 |
Q-CMS135 |
Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
Reported |
None |
None |
0.8406 |
None |
220 |
0 |
263 |
0 |
0.8365 |
0 |
N/A |
PY4 |
DPH |
Ventura County Medical Center |
Q-CAD3 |
Q-KED |
Kidney Health Evaluation for Patients with Diabetes |
Reported |
None |
None |
0.4676 |
None |
1643 |
0 |
3131 |
0 |
0.5248 |
0 |
N/A |
PY4 |
DPH |
Ventura County Medical Center |
Q-IHE1 |
Q-IHE1 |
Improving Health Equity 1Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
Ventura County Medical Center |
Q-IHE2 |
Q-IHE1 |
Chlamydia Screening in Women (CHL) - -American Indian/Alaskan Native |
Reported |
None |
None |
0.4829 |
None |
43 |
0 |
100 |
0 |
0.43 |
0 |
N/A |
PY4 |
DPH |
Ventura County Medical Center |
Q-IHE2 |
Q-IHE2 |
Preventive Care and Screening: Influenza Immunization - -Black/African American |
Reported |
None |
None |
0.478 |
None |
292 |
0 |
647 |
0 |
0.4513 |
0 |
N/A |
PY4 |
DPH |
Ventura County Medical Center |
Q-IHE2 |
Q-IHE2 |
Improving Health Equity 2Â Unlock Metric |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
Ventura County Medical Center |
Q-OA4 |
Q-LBP |
Use of Imaging Studies for Low Back Pain (LBP) |
Reported |
None |
None |
0.8282 |
None |
844 |
0 |
953 |
0 |
0.8856 |
0 |
N/A |
PY4 |
DPH |
Ventura County Medical Center |
Q-PC11 |
Q-CMS69 |
Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan |
Reported |
None |
None |
0.6661 |
None |
16389 |
0 |
25732 |
0 |
0.6369 |
0 |
N/A |
PY4 |
DPH |
Ventura County Medical Center |
Q-PC12 |
Q-CMS147 |
Preventive Care and Screening: Influenza Immunization |
Reported |
None |
None |
0.606 |
None |
18283 |
0 |
30807 |
0 |
0.5935 |
0 |
N/A |
PY4 |
DPH |
Ventura County Medical Center |
Q-PC13 |
Q-CMS2 |
Preventive Care and Screening: Screening for Depression and Follow-Up Plan |
Reported |
None |
None |
0.6511 |
None |
19098 |
0 |
30626 |
0 |
0.6236 |
0 |
N/A |
PY4 |
DPH |
Ventura County Medical Center |
Q-CAD1 |
Q-HBD |
Comprehensive Diabetes Care: HbA1c Poor Control (>9.0%) (CDC-H9)* |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DPH |
Ventura County Medical Center |
Q-CAD1 |
Q-HBD |
Black/African-American |
Reported |
None |
None |
0.377 |
None |
24 |
0 |
63 |
0 |
0.381 |
0 |
N/A |
PY4 |
DPH |
Ventura County Medical Center |
Q-CAD1 |
Q-HBD |
Hispanic/Latino |
Reported |
None |
None |
0.3643 |
None |
695 |
0 |
1894 |
0 |
0.3669 |
0 |
N/A |
PY4 |
DPH |
Ventura County Medical Center |
Q-CAD1 |
Q-HBD |
Total Population |
Reported |
None |
None |
0.3552 |
None |
1103 |
0 |
3091 |
0 |
0.3568 |
0 |
N/A |
PY4 |
DMPH |
Washington Hospital Healthcare System |
Q-CAC3 |
Q-QPP6 |
Coronary Artery Disease (CAD): Antiplatelet Therapy |
Reported |
None |
None |
0.9199 |
None |
176 |
0 |
186 |
0 |
0.9462 |
0 |
N/A |
PY4 |
DMPH |
Washington Hospital Healthcare System |
Q-CAC5 |
Q-CMS347 |
Statin Therapy for the Prevention and Treatment of Cardiovascular Disease |
Reported |
None |
None |
0.6892 |
None |
189 |
0 |
281 |
0 |
0.6726 |
0 |
N/A |
PY4 |
DMPH |
Washington Hospital Healthcare System |
Q-CAD3 |
Q-KED |
Kidney Health Evaluation for Patients with Diabetes |
Reported |
None |
None |
0.4676 |
None |
102 |
0 |
182 |
0 |
0.5604 |
0 |
N/A |
PY4 |
DMPH |
Washington Hospital Healthcare System |
Q-PC12 |
Q-CMS147 |
Preventive Care and Screening: Influenza Immunization |
Reported |
None |
None |
0.476 |
None |
1527 |
0 |
3400 |
0 |
0.4491 |
0 |
N/A |
PY4 |
DMPH |
Washington Hospital Healthcare System |
Q-PC14 |
Q-CMS138 |
Rate 1 (informational only) |
Reported |
None |
None |
0 |
None |
3755 |
0 |
3849 |
0 |
0.9756 |
0 |
N/A |
PY4 |
DMPH |
Washington Hospital Healthcare System |
Q-PC14 |
Q-CMS138 |
Rate 2 |
Reported |
None |
None |
0.2879 |
None |
64 |
0 |
294 |
0 |
0.2177 |
0 |
N/A |
PY4 |
DMPH |
Washington Hospital Healthcare System |
Q-PC14 |
Q-CMS138 |
Rate 3 |
Reported |
None |
None |
0.9195 |
None |
3525 |
0 |
3849 |
0 |
0.9158 |
0 |
N/A |
PY4 |
DMPH |
Washington Hospital Healthcare System |
Q-PC14 |
Q-CMS138 |
Preventative Care and Screening: Tobacco Use - Screening and Cessation Intervention |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
0 |
PY4 |
DMPH |
Washington Hospital Healthcare System |
Q-CAD1 |
Q-HBD |
Comprehensive Diabetes Care: HbA1c Poor Control (>9.0%) (CDC-H9)* |
Reported |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
PY4 |
DMPH |
Washington Hospital Healthcare System |
Q-CAD1 |
Q-HBD |
Black/African-American |
Reported |
None |
None |
N/A |
3 |
None |
1 |
None |
4 |
None |
1 |
N/A |
PY4 |
DMPH |
Washington Hospital Healthcare System |
Q-CAD1 |
Q-HBD |
Hispanic/Latino |
Reported |
None |
None |
0.3406 |
None |
None |
1 |
30 |
0 |
None |
1 |
N/A |
PY4 |
DMPH |
Washington Hospital Healthcare System |
Q-CAD1 |
Q-HBD |
Total Population |
Reported |
None |
None |
0.3406 |
None |
35 |
0 |
165 |
0 |
0.2121 |
0 |
N/A |